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 ABSTRACT 
 
The Janus kinase / signal transducer and activator of transcription (Jak/Stat) signalling cascade 
provides a fast way to transmit signals from cell surface receptors to target genes and is involved in 
numerous pathways including development, growth and immunity. The Jak tyrosine kinase 2 (Tyk2) is 
amongst others involved in type I interferon (IFNα/β) and IL-12 signalling, where it is required for 
full activation of Stats. Mice deficient for Tyk2 on the one hand show increased susceptibility to a 
number of pathogens, but on the other hand are resistant to e.g. lipopolysaccharide- (LPS-) induced 
shock. In the absence of Tyk2, peritoneal macrophages (PMs) show reduced expression of IFNβ, 
IFNα-4 and inducible nitric oxide synthase (iNOS) after LPS treatment.  
The global impact of the absence of Tyk2 on the transcriptional response of PMs to LPS treatment was 
analysed in a whole genome microarray experiment. By reverse-transcription (RT) quantitative real-
time PCR (qPCR) we could confirm the microarray data with respect to reduced expression levels of 
IFNβ and IFN-stimulated genes (ISGs) in the absence of Tyk2 as compared to WT. In addition, six 
genes, that had so far not been described to be regulated in response to LPS or IFN treatment, were 
found to be induced/repressed after LPS treatment in a Tyk2-dependent manner.  
Within another expression profiling experiment, octamer-binding factor 6 (Oct-6; also known as 
Pou3f1, SCIP or Tst-1) was found to be induced in response to IFNβ in a Tyk2-dependent manner in 
fibroblasts. This transcription factor belongs to the family of Pit-Oct-Unc- (POU)- domain containing 
proteins and has been mainly described to be involved in developmental processes, but has not been 
related to immunity yet. We showed for the first time that Oct-6 is expressed in murine fibroblasts and 
macrophages after stimulation with IFNs. Oct-6 was also induced in response to poly(I:C) treatment 
and during viral infections, both in a strictly type I IFN-dependent manner. IFN-mediated induction of 
Oct-6 was largely dependent on the Jak/Stat signalling pathway and we could demonstrate Stat1 
binding to the Oct-6 promoter in response to IFN treatment. With respect to the role of Oct-6, 
overexpression of Oct-6 resulted in prolonged expression of type I IFN mRNAs, but endogenous 
levels of Oct-6 did not impact on IFNα/β expression. However, we could demonstrate that 
endogenous Oct-6 is involved in regulating transcriptional responses to poly(I:C) treatment using 
microarray and RT-qPCR methods comparing the transcriptomes of WT and Oct-6-deficient 
macrophages. More detailed analyses will be required to fully elucidate the role of the novel ISG  
Oct-6 in innate immunity.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ZUSAMMENFASSUNG 
 
Die Signaltransduktionskaskade der Janus kinases und signal transducers and activators of 
transcription (Jak/Stat) stellt eine schnelle Übertragung von Signalen ausgehend von 
Zelloberflächenrezeptoren zu Zielgenen sicher. Sie ist an zahlreichen Prozessen, wie zum Beispiel 
während der Entwicklung, des Wachstums und der Immunantwort, beteiligt. Die Jak tyrosine kinase 2 
(Tyk2) ist unter anderem in die Signaltransduktion von Typ I Interferonen (IFNα/β) und  
IL-12 involviert, wo es für die vollständige Aktivierung der Stats notwendig ist. Tyk2-defiziente 
Mäuse sind einerseits anfälliger auf verschiedenste Pathogene, andererseits resistent gegen 
Lipopolysaccharid- (LPS-) induzierten Endotoxinschock. Peritoneale Makrophagen weisen in 
Abwesenheit von Tyk2 eine reduzierte Expression von IFNβ, IFNα-4 und inducible nitric oxide 
synthase (iNOS) nach LPS Behandlung auf.  
Der globale Einfluss der Tyk2-Defizienz auf die transkriptionelle Antwort peritonealer Makrophagen 
auf LPS-Behandlung wurde mittels Microarray-Technologie analysiert. Unter der Verwendung von 
reverser Transkription (RT) gekoppelt mit quantitativer real-time PCR (qPCR) konnten wir die 
Microarray-Daten bezüglich der reduzierten Expression von IFNβ und IFN-stimulierten Genen (ISG) 
verifizieren. Darüber hinaus wurden sechs weitere Gene gefunden, die bis jetzt nicht als LPS- oder 
IFN-reguliert bekannt waren und die eine Tyk2-abhängige Genregulation aufwiesen.  
Während einer vorangegangenen Studie hatte sich gezeigt, dass octamer-binding factor 6 (Oct-6, alias 
Pou3f1, SCIP, Tst-1) in Fibroblasten durch IFNβ-Behandlung Tyk2-abhängig induzierbar war. Dieser 
Transkriptionsfaktor zählt zu der Familie der Pit-Oct-Unc- (POU-) Domäne-enthaltenden Proteine und 
wurde bis jetzt nur im Zusammenhang mit Prozessen während der Entwicklung, nicht aber in 
Verbindung mit Abläufen im Immunsystem, beschrieben. Wir konnten zum ersten Mal überhaupt 
zeigen, dass Oct-6 durch Behandlung mit IFN in Fibroblasten und Makrophagen induziert wird. 
Außerdem wurde Oct-6 nach poly(I:C)-Behandlung sowie im Zuge von Virusinfektionen produziert, 
was wiederum abhängig von einem funktionierenden Typ I IFN-Signalweg war. Diese IFN-vermittelte 
Oct-6 Induktion war weitestgehend von der Jak/Stat-Signaltransduktionskaskade abhängig. Des 
Weiteren konnten wir belegen, dass Stat1 in Folge von IFN-Behandlung an den Oct-6-Promoter 
bindet. Die Funktion von Oct-6 im Kontext der angeborenen Immunität wurde in Überexpressions- 
und Deletionsexperimenten untersucht. Die Überexpression von Oct-6 führte zu einer verlängerten 
Expression von Typ I IFN mRNAs, allerdings hatte endogenes Oct-6 keinen Einfluß darauf. Dass  
Oct-6 eine Rolle im Zuge einer Immunantwort spielt, wurde gezeigt, indem die Antworten von WT 
und Oct-6-defizienten Makrophagen auf poly(I:C)-Behandlung mittels Microarrays und RT-qPCR 
verglichen wurden. Um die Rolle des neuen ISG Oct-6 im Zuge der angeborenen Immunität 
vollständig zu erfassen, sind weitere, detailliertere Analysen notwendig.  
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Introduction   1 
I N T R O D U C T I O N  
 
The immune system  
In order to provide effective defence against invading pathogens, jawed vertebrates have developed a 
sophisticated immune system consisting of two complementary parts. The adaptive immune system 
mediates highly specific responses against virtually any pathogen. Genetic rearrangements and 
somatic hypermutation of antigen-receptor genes allow for the detection and consequently the 
elimination of potential antigenic components. Moreover the adaptive immune system is able to 
remember a pathogen once encountered and will fight it immediately next time meeting a known 
insult. However, launching this kind of immune response for the first time takes about one week, 
which would be far too long to cope with an immediate threat. The innate immune system is able to 
react immediately to invading pathogens. From the evolutionary point of view the innate immune 
system is quite old, as it is found in invertebrates and vertebrates as well as in plants. It relies on 
germline encoded receptors, so-called pattern recognition receptors (PRRs) that recognise structures 
conserved amongst pathogens, but not present in the host, such as bacterial proteins, cell wall 
components, or nucleic acids of bacterial or viral origin (Carpenter and O'Neill, 2007). PRRs also 
recognise endogenous components, danger signals, such as degradation products of macromolecules 
or extracellular breakdown products, that are generated upon tissue damage. On the one hand PRR-
mediated signalling in response to endogenous ligands is necessary for the initiation of tissue 
regeneration processes. On the other hand it is critically involved in the pathogenesis of autoimmune 
diseases such as systemic lupus erythematosus (Zhang and Schluesener, 2006).  
 
The interferon system 
Interferons (IFNs) were found more than 50 years ago as secreted molecules that interfere with viral 
replication. Intensive research over the last decades has revealed that IFNs are pleiotropic cytokines 
that exhibit antiviral, antiproliferative and immunomodulatory effects. IFNs inhibit initial infection 
and virus replication and thus limit virus spread until the adaptive immune system has launched an 
effective cell-mediated and humoral response to the infection. Without IFNs, an organism would 
succumb to viral, as well as bacterial infection, which was shown in mice lacking IFN or components 
of the downstream signalling pathways. IFNs also have a pronounced anti-proliferative effect as they 
are able to induce apoptosis in a number of documented malignancies including herpesvirus-associated 
lymphomas, acute promyelotic leukemia, non-small-cell lung cancer, non-melanoma skin cancer and 
glioma. Moreover, IFNs exhibit an immunomodulatory role as they can mediate the activation and 
recruitment of the adaptive immune response (Barber, 2001; Schroder et al., 2004; Krause and Pestka, 
2007).  
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IFNs are grouped into three classes, i.e. the type I, II and III IFNs, based on structural similarities and 
receptor usage. Members of the type I IFNs, their induction and effects will be described in detail 
below.  
There is only one type II IFN, which is IFNγ. This cytokine is mainly produced by natural killer (NK) 
cells during the early immune response, and by activated T-cells in the course of the adaptive immune 
response. IFNγ plays a prominent role in macrophage activation, as it induces direct antimicrobial and 
antitumor mechanisms, antigen processing and presentation pathways. Moreover, IFNγ mediates 
leukocyte attraction and directs growth, maturation, and differentiation of many cell types. It enhances 
NK-cell activity and regulates B-cell functions such as immunoglobulin (Ig) production and class 
switching (Schroder et al., 2004).  
Only recently the class of type III IFNs has been established. IFNλ1 (or IL-29), IFNλ2 (IL-28A) and 
IFNλ3 (IL-28B) are in many ways similar to type I IFNs. Although they differ from type I IFNs in 
their structure as well as in their cognate receptor, they signal via the same pathway, induce expression 
of similar (or the same) target genes and thus lead to similar effects (Ank et al., 2006). The IFNλ 
receptor consists of two subunits, namely IL10R2, which is ubiquitously expressed, and IL28RA, 
which is expressed only on a limited number of cell types. This cell type specific expression of the 
IFNλ receptor constitutes the major difference between the type I and type III IFN systems (Uzé and 
Monneron).  
 
Type I IFNs  
The class of type I IFNs contains the multi-gene family of IFNαs (IFNα-1 through -14), and the single 
copy genes IFNβ, IFNε, IFNκ, IFNω and IFNζ/limitin, all of which are encoded by intron-less genes 
and are clustered on mouse chromosome 4. They bind to a common receptor, the IFNα/β receptor 
consisting of the two subunits Ifnar1 and Ifnar2 (Krause and Pestka, 2007).  
 
Induction of type I IFNs 
In line with their essential role in innate immunity, type I IFNs (especially IFNα/β) can be produced 
by almost all cell types. Large amounts are rapidly and transiently induced upon recognition of viral or 
other microbial infections via PRRs. So far two major receptor families of PRRs have been shown to 
function in the innate immune system and induce type I IFNs in response to ligand recognition: (i) the 
membrane bound Toll-like receptors (TLRs), and (ii) the retinoic acid-inducible gene I (RIG-I)-like 
helicases (RLHs), which are found in the cytosol (Carpenter and O'Neill, 2007). In addition and only 
discovered recently, cytosolic DNA sensors are also able to induce IFNα/β (Vilaysane and Muruve, 
2009).  
 
Introduction   3 
Induction of type I IFNs through TLR signalling  
The family of TLR receptors is highly conserved throughout evolution and homologues have been 
found in Drosophila melanogaster as well as in Caenorhabditis elegans. So far 13 mammalian TLRs 
have been identified (table 1). Together with the interleukin (IL)-1 receptors, the TLRs form a receptor 
superfamily (IL-1/TLR superfamily), which is characterised by the common cytosolic Toll-IL-1-
receptor (TIR)-domain. In contrast to the IL-1 receptors, which have an immunoglobulin-like 
structured extracellular domain, the extracellular domains of TLRs contain leucine rich repeats. Each 
TLR, alone or in combination with another TLR or an accessory protein, is specific for a certain set of 
ligands (Akira et al., 2006). 
 
Table 1: Mammalian TLRs and their ligands, adapted from (Akira et al., 2006).  
TLR Ligand Organisms  
TLR1 Triacyl-lipopeptides Bacteria 
TLR2 
Peptidoglycan, lipoprotein, lipopeptides, atypical LPS Bacteria 
Zymosan, phospholipomannan Fungi 
GPI anchor Protozoa 
VV (Barbalat et al., 2009)  Virus 
TLR3 
Poly(I:C), dsRNA Viruses 
mRNA (Karikó et al., 2004) endogenous 
TLR4 
Lipopolysaccharide (LPS) Bacteria 
Mannan, glucuronoxylomannan Fungi 
Glycoinositolphospholipids Protozoa 
RSV fusion protein 
MMTV envelope protein (Lee and Kim, 2007)  
VSV G protein (Krishnan et al., 2007)  
Viruses 
heat shock proteins, fibronectin,  
hyaluronan (Krishnan et al., 2007)  endogenous 
TLR5 Flagellin Bacteria 
TLR6 
Diacyl-lipopeptides 
Lipoteichoic acids (Lee and Kim, 2007) Bacteria 
Zymosan (Lee and Kim, 2007) Fungi 
TLR7/TLR8 Synthetic imidazoquinoline-like molecules, ssRNA Viruses 
TLR9 
CpG DNA  Batceria, Protozoa, Viruses 
DNA sugar backbone (Haas et al., 2008) all 
Hemozoin  Protozoa 
TLR101 unknown (Hasan et al., 2005)   
TLR11 
component of uropathogenic bacteria Bacteria 
Profilin-like molecule Protozoa 
TLR122 unknown (Krishnan et al., 2007)  
TLR132 unknown (Krishnan et al., 2007)  
 
VV: Vaccinia virus, RSV: respiratory syncytial virus, MMTV: mouse mammary tumor virus, VSV: vesicular 
stomatitis virus 
1 TLR10 is not functional in mice due to disruption by retroviral insertion; 2 TLR12, 13 are not found in humans 
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TLRs are membrane bound, whereby TLR1, TLR2, TLR5, TLR6, TLR10, TLR11, TLR12 and TLR13 
are located in the plasma membrane, TLR3, TLR7, TLR8 and TLR9 are found in the membrane of the 
endosomal compartment (Akira et al., 2006; Kawai and Akira, 2008). TLR4 is found in the 
cytoplasmic as well as in the endosomal membrane (Kagan et al., 2008). Similarly, TLR2 after 
internalisation and endosomal/lysosomal localisation mediates type I IFN induction in response to VV 
infection (Barbalat et al., 2009). All TLRs, except for TLR3, activate a signalling pathway that 
involves the adaptor molecule MyD88, resulting in the activation of the transcription factors NFκB 
and AP-1. Upon activation they induce the expression of proinflammatory genes, such as TNFα, IL-6, 
IL-1β and IL-12 (Figure 1). A subset of TLRs, basically those that locate to the endosomal 
compartment, initiate signalling cascades leading to the induction of IFNβ. The induction of IFNβ in 
response to the ligands of TLR3 and TLR4, is mediated via the activation of IFN regulatory factor 3 
(Irf3) in a MyD88-independent, but TRIF-dependent manner (Figure 1) (Uematsu and Akira, 2007).  
 
 
Figure 1. TLR3- and TLR4-mediated signalling pathways (adapted from Uematsu and Akira, 
2007). TLR signalling pathways originate from the cytoplasmic TIR domain. Upon ligand binding 
the adapter protein MyD88 (myeloid differentiation primary response gene 88) associates with the 
TLRs and recruits IRAKs (interleukin-1 receptor-associated kinases) to the receptor. IRAKs then 
activate TRAF6 (TNF-receptor-associated factor 6), leading to the activation of TAK1 
(transforming growth factor-β-activated kinase). TAK1 activates the IKK (inhibitor of NFκB 
kinase) complex consisting of IKKα, IKKβ, and NEMO/IKKγ. The IKK complex phosphorylates 
IκB (inhibitor of NFκB), which is degraded resulting in nuclear translocation of NFκB (nuclear 
factor-κB), which induces expression of proinflammatory cytokines. Another adapter, TRIF (TIR 
domain-containing adapter protein inducing IFNβ), is responsible for TLR3- and TLR4-mediated 
Irf3 activation. Additionally, TLR4 also requires yet another adapter, TRAM (TRIF-related 
adaptor molecule), for Irf3 activation. TRIF interacts with NAP1 (NAK-associated protein 1; in 
complex with TANK (TRAF-family member associated NF-κB activator)/SINTBAD (similar to 
NAP1 TBK1 adaptor); complemented from Nakhaei et al., 2009) TBK1 (TANK-binding kinase 
1), IKKι, RIP1 (receptor-interacting protein-1), and TRAF6. Irf3 is activated by TBK1 and IKKι, 
which mediate Irf3 phosphorylation and stimulate its nuclear translocation, DNA-binding and 
induction of IFNβ, IP-10 and Rantes expression. 
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Induction of type I IFNs through RLH signalling 
The existence of cytoplasmic RNA receptors had been postulated based on the fact that cells deficient 
for TLR3 could still respond to intracellular poly(I:C) and induce IFNβ to wild type levels. The RNA 
helicases, RIG-I and Mda5 (melanoma differentiation associated protein-5) were shown to bind to 
viral RNA and poly(I:C), although with different specificity, and induce a signalling cascade resulting 
in the induction of IFNβ and inflammatory cytokines. In addition to a DExD/H-box RNA-helicase 
domain, Rig-I and Mda5 harbour two caspase recruiting domain (CARD)-like domains, which are 
necessary for downstream signalling. Another member of the family is Lgp2 RIG-I-like receptor 
Lgp2), which lacks these CARD-like domains and is supposed to interfere with RIG-I signalling by 
competing for the ligand. In contrast, Lgp2 is needed for full induction of type I IFNs in the case of 
Mda-5 signalling (Figure 2) (Takeuchi and Akira, 2007; Kawai and Akira, 2008; Nakhaei et al., 2009).  
 
 
 
Figure 2: Signalling pathways downstream of RLHs (adapted from Takeuchi and Akira, 2007). 
Following ligand binding, RIG-I or MDA-5 associate with the adapter IPS-1 via the CARD-like 
domains. IPS-1 (IFNβ promoter stimulator 1) is located to mitochondria and initiates two 
signalling pathways leading to activation of Irf3 or NFκB, and finally to the expression of IFNβ or 
proinflammatory cytokines, respectively. A complex consisting of TRADD (TNF receptor 1 
associated signal transducer), TRAF6, TRAF2, and RIP1 (not depicted, complemented from 
Nakhaei et al., 2009) signals from IPS-1 to a FADD (Fas-associated via death domain), caspase-8, 
and caspase-10 conatining complex which leads to NFκB activation. IPS-1 signals via TRAF3 and 
a complex of TANK, NEMO (complemented from Nakhaei et al., 2009), NAP1, SINTBAD, 
TBK1 and IKKι to activate Irf3 and Irf7. Ddx3x (DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 3, X-linked) is also activated by TBK1 and is necessary for full induction of IFNβ (not 
depicted, complemented from (Soulat et al., 2008; Schröder et al., 2008)).  
 
 
Introduction   6 
Induction of type I IFNs through cytosolic DNA sensors  
The fact that cytosolic DNA induces expression of IFNβ independent of TLR and RLH signalling, 
argues for the existence of (a) cytoplasmic sensor(s). DAI (DNA dependent activator of Irfs; or Zbp1 
for Z-DNA-binding protein 1) was reported to be involved in IFNβ induction in response to Z-DNA, 
B-DNA and herpes simplex virus (HSV) infection. The induction was shown to be mediated by a 
TBK1 dependent activation of Irf3 (Vilaysane and Muruve, 2009). Only recently, Zbp1, Irf3 and 
Ddx3x were shown to be involved in induction of type I IFNs after human cytomegalovirus (HCMV) 
infection (Defilippis et al., 2009). However, cytosolic DNA induced IFNβ was only partially reduced 
upon knockdown of DAI (Vilaysane and Muruve, 2009). Moreover, DNA-mediated activation of 
immune responses was observed to be almost normally in DAI-deficient mice (Ishii et al., 2008). This 
argues for the presence of at least one other cytosolic DNA receptor. Very recently, the DNA 
dependent RNA polymerase III (PolIII) has been shown to recognise cytosolic AT-rich dsDNA and 
transcribe it into AU-rich dsRNA containing a 5’triphosphate (Chiu et al., 2009). This RNA in turn is 
recognised by Rig-I which induces a signalling cascade resulting in the induction of IFNβ, as 
described above (Figure 2). AIM2 has been found to also bind to cytosolic dsDNA and, by activation 
of the inflammasome, leads to processing and secretion of IL-1β but not to the induction of type I 
IFNs (Vilaysane and Muruve, 2009).  
 
 
Transcriptional regulation of IFNβ  
The enhancer of the IFNβ gene is located -102 to -47 bp upstream of the transcription start and has 
been subdivided into four so-called positive regulatory domains (PRD I through IV). Coordinate 
activation and binding of the transcription factors Irf3 and/or Irf7, ATF-2/c-Jun and NFκB (p50/p65) 
to this enhancer element are crucial for the expression of IFNβ. Together with the architectural protein 
HMG-I(Y) they form a complex known as the enhanceosome (Figure 3) (Honda et al., 2006; Panne, 
2008).  
Especially Irf3 and the highly homologous Irf7 are key regulators of type I IFN expression. Irf3 is 
constitutively expressed in most cell types and  localises to the cytoplasm as long as it is in the latent, 
non-activated state. Upon activation by phosphorylation, Irf3 dimerises and translocates to the 
nucleus. In contrast, Irf7 is expressed only at rather low levels in most cell types, but the levels are 
rapidly increased in response to type I IFN signalling. Similar to Irf3, Irf7 also requires 
phosphorylation for its activation, dimerisation (either homodimers, or heterodimers with Irf3) and 
nuclear translocation (Honda et al., 2006; Génin et al., 2009). 
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Figure 3: Assembly of the IFNβ enhanceosome and IFNβ gene induction (adapted from Honda 
et al., 2006). (A) In the steady state, the transcription start site of the IFNβ gene is covered by a 
positioned nucleosome. (B) PRD I-IV direct the assembly of ATF-2/c-Jun, Irfs, NFκB, and HMG-
I(Y). The enhanceosome recruits histone acetyltransferases, such as GCN5 and CBP/p300, which 
acetylate (Ac) a subset of lysine residues of histones in the nucleosome. (C) Next, the RNA 
polymerase II holoenzyme (lacking the transcription factor TFIID) is recruited to the promoter. 
Chromatin-remodeling complexes such as BAF complexes are then recruited by contacting the 
acetylated histone. (D) BAF complexes induce nucleosome displacement from the transcription 
start site, making it accessible to TFIID for the induction of IFNβ expression. 
 
 
 
Type I IFN signalling 
The canonical Jak/Stat pathway 
All type I IFNs bind to a common receptor, the IFNα/β receptor (Ifnar) consisting of two subunits, 
namely Ifnar1 and Ifnar2. Members of the Janus protein tyrosine kinases (Jaks) are constitutively 
associated with the cytoplasmic domains of the receptor chains, which lack intrinsic kinase activities. 
Tyk2 and Jak1 are associated with Ifnar1 and Ifnar2, respectively. Upon ligand binding the receptor 
complex undergoes conformational changes which results in the activation of the associated kinases. 
Jak1 and Tyk2 undergo auto- and cross-phosphorylation, and phosphorylate the receptor chains. This 
allows binding of preformed, but inactive, dimers of signal transducers and activators of transcription 
(Stats) to phosphorylated tyrosine residues of the receptor. Stats get phosphorylated, undergo 
conformational changes and translocate to the nucleus, where they initiate transcritpion of IFN-
stimulated genes (ISGs; Figure 4) (Schindler et al., 2007). In response to type I IFN mainly Stat1/Stat2 
heterodimers are formed, which associate with another transcription factor, Irf9. Together they form 
the transcription factor complex IFN-stimulated gene factor 3 (ISGF3), which binds to promoters 
containing an interferon stimulated response element (ISRE; GATTTC(N)2TTTCNY; Decker et al., 
1997). To a lesser extent also Stat1 homodimers are activated, which induce the expression of genes 
containing a IFNγ activated site (GAS; TTC(N)2-4GAA; Decker et al., 1997) in their promoter 
(Horvath, 2000; Takaoka and Yanai, 2006).  
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Figure 4: Jak/Stat signalling pathway downstream of type I IFNs (www.jak-stat.at). Ligand-
binding initiates a phosphorylation cascade mediated by the Jaks, Jak1 and Tyk2. Activated 
Stat1/Stat2 and to a lesser extent Stat1/Stat1 dimers translocate to the nucleus and induce the 
transcription of IFN-responsive genes.  
 
Apart from Stat1 and Stat2 other Stats can be activated in response to type I IFNs. Actually, type I 
IFNs seem to be unique amongst all cytokines in that they are able to activate all seven Stats, which 
seems to be largely dependent on the cell type and the activation status of the cells (van Boxel-Dezaire 
et al., 2006).  
 
Pathways additionally activated by type I IFNs 
In addition to the canonical Jak/Stat pathway, type I IFNs activate other pathways involving various 
kinases and transcription factors, which altogether mediate the complex responses to type I IFNs 
(Figure 5) (Stark, 2007). Activation of the phosphatidylinositol-3’-kinase (PI3-kinase) and its 
downstream signalling has been shown to play an important role in mediating effects of type I IFN, i.e. 
regulation of gene induction and initiation of translation (Kaur et al., 2005). Another pathway 
critically involved in mediating the pleiotropic effects of type I IFN signalling is the mitogen-activated 
protein (MAP) kinase pathway. Three major MAP kinase pathways, namely the p38 MAP kinase, the 
extracellular signal-regulated kinase (ERK) and the c-Jun NH2-terminal kinase (JNK) pathway, are 
activated in response to type I IFN signalling (Katsoulidis et al., 2005).  
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Figure 5: Complexity of the responses to type I IFNs (adapted from Stark, 2007). In addition to 
the activation of Jaks and Stats, type I IFNs activate other kinases and transcription factors (TFs), 
as indicated in detail in the figure. The patterns of Stat, TF and kinase activation in response to 
each specific IFN are likely to be dependent on the cell type. Some genes respond only to activated 
Stats, some only to activated TFs, such as activated Irfs and/or the Ets-family member PU.1 
(EIRE: Ets/Irf responsive element; EICE: Ets/Irf composite element), and some genes require 
binding of Stats together with other TFs. 
 
 
Biological effects of type I IFNs  
IFN treatment results in the induction of hundreds of IFN-stimulated genes (ISGs) (Der et al., 1998). 
Direct antiviral activities have been attributed to only a few of these gene products, e.g. Myxovirus 
resistance gene 1 and 2 (Mx1, Mx2), 2’,5’-oligoadenylate synthetases (Oas), ribonuclease L 
(RNaseL), dsRNA-dependent, protein kinase R (Pkr) and IFN-stimulated protein of 15 kDa (Isg15). 
Other ISGs encode PRRs (e.g. Rig-I, TLR3; de Veer et al., 2001; Ifi200 class of genes: e.g. AIM2) or 
transcription factors (e.g. Irf7, Stat1; Der et al., 1998), which are involved in feed forward loops, 
leading to an amplification of type I IFN production and thus resulting in further protection from virus 
spread and disease (Sadler and Williams, 2008).  
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Two tetratriocopeptide motif containing proteins, ISG54 and ISG56, have been shown to be 
implicated in inhibition of translation (Terenzi et al., 2006). Members of the IFI200-family are 
involved in regulation of cell growth and differentiation (Asefa et al., 2004). Type I IFNs initiate 
pathways leading to apoptosis, e.g. by inducing TNF-related apoptosis inducing ligand, Fas antigen, or 
caspases 4 and 8 (de Veer et al., 2001). The growth arrest/cell death induced by type I IFNs 
contributes to the anitiviral effect, as viral replication is dependent on cellular replication and cell 
survival. Antiproliferative effects of type I IFNs are also exploited for treating several types of cancer, 
e.g. hairy cell leukemia, chronic myeloid leukemia, myeloma and B- and T-cell lymphomas. A 
number of solid tumors have also been shown to be responsive to IFN, including melanoma, renal cell 
carcinoma, and midgut carcinoids. Moreover, premalignant virally induced neoplasms, such as human 
papillomavirus related papillomas are also responsive to IFN treatment (Pokrovskaja et al., 2005). 
Type I IFNs exert multiple functions on cells of the innate as well as the adaptive immune system, e.g. 
macrophages, dendritic cells, NK-cells, T-cell subsets and B-cells. The reported effects of type I IFNs 
are highly dependent on the overall context of the immune response investigated, i.e. on the amount of 
type I IFN, the diverse subtypes of type I IFNs, the stimulus, additional cytokines and the cell types 
involved (Bogdan et al., 2004).  
 
Introduction   11 
The POU-family of transcription factors 
Members of the Pit-Oct-Unc- (POU-) family of transcription factors are involved in a variety of 
cellular processes, ranging from house-keeping gene function (Oct-1) and programming of embryonic 
stem cells (Oct-4), to the development of the immune system (Oct-1 and Oct-2), the pituitary gland 
(Pit-1) or the nervous system (Brn-1 through -4 and Oct-6) (Ryan and Rosenfeld, 1997; Phillips and 
Luisi, 2000). The transcription factors are characterised by the highly conserved structure of their 
DNA-binding domain, the POU-domain. This domain consists of 150-160 amino acids and is named 
after the first four transcription factors found to contain this conserved domain, namely the 
mammalian proteins Pit-1, Oct-1 and Oct-2, and the Caenorhabditis elegans protein Unc86. The POU-
domain itself is a bipartite domain, divided into the N-terminal POU-specific domain, which is unique 
to the transcription factors of this family, and the C-terminal POU-homeodomain. The latter is related 
to the domain found in members of the homeobox-transcription factor family, which is involved in 
various developmental processes. The POU-specific domain and the POU-homeodomain are separated 
by a variable linker region of 15 to 56 amino acids (Figure 6) (Herr and Cleary, 1995; Phillips and 
Luisi, 2000).  
 
Figure 6: The conserved DNA-binding domain of POU-transcription factors.. The POU-
domain consists of two sub-domains, i.e. the POU-specific domain (POUS) and the POU-
homeodomain (POUH). These are connected by a flexible linker, which shows high variability 
among the different classes of POU-proteins (adapted from Herr and Cleary, 1995).  
 
The members of the POU-family of proteins are divided into six classes according to amino acid 
sequence similarities of the POU-domain and to the conservation of the variable linker region. For 
example, the ubiquitously expressed Oct-1 and the tissue specific Oct-2, which has been found in B-
cells (Shivdasani and Orkin, 1996), in peripheral-blood monocytes (PBMCs) and macrophages 
(Neumann et al., 2000), belong to the second class and have been renamed to Pou2f1 and Pou2f2, 
respectively. The embryonic stem cell-specific Oct-4 was assigned to the fifth class and is now called 
Pou5f1. Oct-6 (Pou3f1), Brn-2 (Pou3f2), Brn-1 (Pou3f3) and Brn-4 (Pou3f4), all of which are mainly 
involved in processes of nervous system development, constitute the third class of POU-proteins (table 
2) (Ryan and Rosenfeld, 1997; Phillips and Luisi, 2000; Holland et al., 2007).  
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Table 2: The POU-family of transcription factors (adapted from Ryan and Rosenfeld, 1997 and 
Holland et al., 2007).  
Class Name also known as expressed in (according to current literature) 
I Pou1f1 Pit-1 pituitary gland 
II 
Pou2f1 Oct-1, Otf1 ubiquitously 
Pou2f2 Oct-2, Otf2 B-cells, macrophages, PBMCs 
Pou2f3 Oct-11, Skn-1a squamous epithelia, keratinocytes 
III 
Pou3f1 Oct-6, Tst-1, SCIP Schwann cells, neuronal subpopulations, keratinocytes 
Pou3f2 Brn-2, Oct-7, Otf7 central nervous system, oligodendrocytes, Schwann cells 
Pou3f3 Brn-1, Otf8 central nervous system 
Pou3f4 Brn-4, Otf9, Dfn3 neuronal cells 
IV 
Pou4f1 Brn-3a sensory nervous system, B- and T-cells 
Pou4f2 Brn-3b, Brn3.2 retina, subpopulation of ganglion cells 
Pou4f3 Brn-3c, Dfna15 ear sensory epithelial cells 
V 
Pou5f1 Oct-4, Oct-3 embryonic stem cells 
Pou5f2 Sprm-1 male germ cells 
VI 
Pou6f1 Brn-5, Tcfb1 nervous system, Schwann cells 
Pou6f2 Wt5, Wtsl, Rpf-1 retinal ganglion, kidney 
 
 
DNA-binding of the POU-transcription factors 
POU-domain transcription factors recognise a sequence known as the octamer consensus motif 
(ATGCAAAT/A) or variants thereof. One variant is the “palindromic Oct-factor recognition element” 
(PORE; ATTTGAAATGCAAAT), which was first identified as an Oct-4 responsive DNA element in 
the first intron of the osteopontin gene. Another variant is the consensus sequence “more of PORE” 
(MORE; ATGCATATGCAT) element of the immunoglobulin heavy chain enhancers, which are 
regulated by Oct-1 and Oct-2 (Reményi et al., 2002). Other members of the POU-family also 
recognise and bind to the consensus octamer sequence, but this might not be their highest affinity 
binding site. POU-proteins, however, have diverged sufficiently, so that their specifically preferred 
binding sites differ from the consensus sequence (Herr and Cleary, 1995). For example, the consensus 
recognition sequence for members of the third class of POU-proteins, including Oct-6, is  
CAT(N)0-3T/AAAT (Figure 7B). Oct-1 and Pit-1 have been most intensively studied with respect to 
their crystal structure and DNA-binding properties. The POU-specific domain and the POU-
homeodomain were shown to bind independently to distinct regions of the recognised element, the 
linker region is enforcing the cooperative binding. POU-proteins were shown to be highly flexible in 
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terms of orientation of the two DNA-binding subdomains when bound to DNA. In general, the  
arrangement of the POU domain on the DNA, and thereby its DNA-binding affinity, and sequence 
specificity seems to be dependent on the linker region, the surrounding DNA sequence, and potential 
binding partners (Figure 7) (Herr and Cleary, 1995; Phillips and Luisi, 2000; Reményi et al., 2002).  
 
 
 
 
Figure 7: Flexibility of POU-proteins in their arrangement on DNA.  (A) Based on the 
example of Oct-1 and Brn-2, the scheme shows, how the arrangements on the DNA differ in the 
relative orientation of the two subdomains, on the spacing between the POU-specific- (POUS) and 
the POU-homeodomain (POUH), and on the positioning of the two subdomains. POUS and POUH 
domain-binding sites are underlined and overlined, respectively (Herr and Cleary, 1995). (B) 
Summary of the identified DNA recognition elements for members of POU-III class according to 
their spacing preferences (modified from (Li et al., 1993); Ddc, dopa decarboxylase; vvl, ventral 
veins lacking (drifter); D.m., Drosophila melanogaster; Mpz, Myelin protein zero; M.m., Mus 
musculus; Crh, corticotropin releasing hormone; R.n., Rattus norvegicus).  
 
POU-proteins show varying binding preferences, as they can act as monomers, homodimers, or form 
heterodimers with other POU-family members (Herr and Cleary, 1995). Additionally, POU-proteins 
display a high flexibility in cooperating with heterologous, non-POU transcription factors of cellular 
or even viral origin. Members of the high mobility-group (HMG) domain family are known to interact 
with homeodomain containing proteins in general. Especially, members of a subfamily, the Sry-box 
containing (Sox) proteins, were shown to specifically interact with members of the POU-family 
(Dailey and Basilico, 2001). Moreover, viral proteins, for example VP16 of Herpes simplex virus and 
T-antigen of JC virus (a human polyomavirus causing progressive multifocal leukoencephalopathy), 
were found to interact with the POU-proteins Oct-1 and Oct-6, respectively (Latchman, 1999). Oct-1 
binding to an octamer motif in the viral promoter of the immediate early genes and subsequent 
association of VP16 with Oct-1 are necessary to initiate lytic infection. Similarly, Oct-6 binds to the 
promoter of JC virus early and late genes and in coorperation with JC virus T-antigen activates viral 
gene transcription resulting in the glial-cell tropism of JC virus.  
(A) 
(B) 
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Oct-6 (Pou3f1, SCIP, Tst-1) 
Octamer-binding factor 6 (Oct-6), also known as suppressed cAMP-inducible POU protein (SCIP, 
(Monuki et al., 1989)), or Testes-1 (He et al., 1989) is encoded by an intronless gene on mouse 
chromosome 4, which shows all characteristics of a retroposed pseudogene (Kuhn et al., 1991). The 
45 kDa Oct-6 protein consists of 449 amino acids, the N-terminal third encoding a glycine- and 
alanine-rich transcriptional effector domain, followed by the DNA-binding POU-domain and a 
proline-rich sequence of so far unknown function (Meijer et al., 1992; Monuki et al., 1993).  
 
Expression and regulation of Oct-6 
Oct-6 belongs to the third class of POU domain transcription factors and plays an essential role in the 
terminal differentiation of myelinating Schwann cells and squamous epithelia (Jaegle et al., 1996; 
Faus et al., 1994; Andersen et al., 1997). Expression of Oct-6 was also observed in undifferentiated 
embryonic carcinoma cells (P19 EC; Meijer et al., 1990), during early embryogenesis, in developing 
neural and glial cells (Monuki et al., 1989), in cells of neonatal testes (He et al., 1989) and pancreatic 
β-cells (Baumeister and Meyerhof, 2000).  
Expression of Oct-6 is tightly controlled, although the mechanisms, the cis-acting elements, and the 
signalling pathways leading to its expression are largely unknown. Proximal promoter elements, the 
transcription start site, the TATA box and a CCAAT motif have been identified, but are suggested to 
be responsible only for maintaining a basal expression of Oct-6 (Kuhn et al., 1991). Tissue-specific 
and time-dependent expression of Oct-6 is regulated by distal enhancer elements. For example ~5 kb 
upstream of the transcription start a sequence element responsive to estrogen has been identified 
(Renner et al., 1996). Another enhancer element ~12 kb downstream of the transcription start site was 
identified, which was shown to be responsible for Schwann cell-specific expression of Oct-6 (SCE for 
Schwann cell specific enhancer; Mandemakers et al., 2000). 
Oct-6 contains a nuclear localisation signal (NLS; Figure 8) within the POU-homeodomain, which is 
conserved in other POU-family members. Accordingly, Oct-6 protein is found mainly in the nucleus. 
Since Oct-6 shows potential phosphorylation sites near the NLS, it was suggested that the nuclear 
import of Oct-6 might be influenced/controlled by phosphorylation, but phosphorylated Oct-6 has not 
been detected yet. A nuclear export signal (NES; Figure 8) is located in the POU-homeodomain of 
Oct-6, which also seems to be conserved among all POU-family members. Regulation of nuclear 
import/export might be one means of regulating the activity of Oct-6 as a transcription factor, as 
similar mechanisms have already been shown for Oct-1 in Xenopus and Brn-2 in murine development 
(Baranek et al., 2005 and references therein). 
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Figure 8: Schematic representation of the murine Oct-6 protein (adapted from Baranek et al., 
2005). The POU-specific domain (POUS) and the POU-homeodomain (POUH), the latter 
consisting of three helices (H1, H2 and H3), are indicated, as are the locations of the NLS and the 
NES within the POU-homeodomain. 
 
The Role of Oct-6 in Schwann cell development 
Oct-6 has been analysed mainly with respect to its role in Schwann cell development. Schwann cells 
are the glial cells of the peripheral nervous system. They originate from cells of the neural crest, a 
transient group of cells of the dorsal part of the neural tube, which also gives rise to melanocytes and 
neuronal precursors. Schwann cell precursors develop into immature Schwann cells which finally 
differentiate into myelinating and non-myelinating Schwann cells. While myelinating Schwann cells 
build up the myelin sheath, which is necessary for fast conduction velocity (saltatory conduction) 
along the axon, non-myelinating Schwann cells are crucial for neuronal survival. A myelinating 
phenotype is first defined by a Schwann cell forming an one-to-one association with an axon. This 
promyelinating Schwann cell then forms the myelin sheath within a few days. Myelin is a multi-
lamellar structure formed by spiral wrapping of the cell membrane, which contains mainly the 
structural proteins myelin protein zero (Mpz, P0), myelin basic protein (Mbp), peripheral myelin 
protein 22 (Pmp22) and myelin-associated glycoprotein (Mag) (Mirsky et al., 2001).  
By postnatal day 30 (P30) the onset of myelination is complete and all Schwann cells show either a 
myelinating or non-myelinating phenotype. The maintenance of the myelinating phenotype is 
dependent on axonal contact, in developing as well as in regenerating nerves (Scherer et al., 1994). 
Only recently, a G-protein coupled receptor family member, Gpr126, was found to be involved in 
elevating cAMP levels and leading to induction of Oct-6 and initiating myelination in zebrafish (Monk 
et al., 2009). However, the axonal ligand has not been identified yet, and involvement of other 
receptors cannot be excluded. Signalling involves cAMP second messenger, and drugs such as 
forskolin inducing cAMP also induce Oct-6 expression (Svaren and Meijer, 2008; Meijer, 2009). 
Protein kinase A (PKA) is activated by cAMP signalling and further phosphorylates/activates cAMP 
response element binding protein and NFκB, both of which are involved in Oct-6 expression. 
Moreover, type III neuregulin 1 (Nrg1) mediated activation of PI3K/Akt and Ras/MAPK pathways 
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leading to Schwann cell proliferation and survival might also be involved in the regulation of Oct-6 
expression (Svaren and Meijer, 2008; Birchmeier and Nave, 2008).  
Oct-6 (Jaegle et al., 1996; Bermingham et al., 1996; Ghazvini et al., 2002) and Egr2 (Krox20; Topilko 
et al., 1994) are the two main transcription factors responsible for the correct development of 
myelinating Schwann cells, as deleting either factor leads to a block in myelination. Expression of 
Oct-6 is transiently upregulated in proliferating, promyelinating Schwann cells with expression levels 
peaking between P1 and P10. As myelination progresses Oct-6 expression decreases sharply (Arroyo 
et al., 1998). Oct-6-deficient animals die soon after birth from a breathing insufficiency, caused by 
defective migration and differentiation of certain neurons in the brainstem. Only 2 to 4% of 
homozygous Oct-6-deficient mice have been reported to survive (Jaegle et al., 1996; Bermingham et 
al., 1996). Studies in those survivors and in mice with a Schwann cell specific knockout of Oct-6 
(ΔSCE; Ghazvini et al., 2002) reported severe defects in peripheral myelination and Schwann cells are 
arrested in the promyelinating stage. Thus, Oct-6 seems to be essential for terminal differentiation of 
myelinating Schwann cells (Figure 9). However, in the absence of Oct-6 the myelination is not 
completely blocked but only considerably delayed (by 10 to 15 days; Jaegle et al., 1996; Bermingham 
et al., 1996; Ghazvini et al., 2002). In contrast, deleting Egr2 leads to a continuous block of 
myelination. Egr2 was shown to be a target gene of Oct-6, as in the absence of Oct-6 the expression of 
Egr2 is reduced (Ghislain et al., 2002).  
 
 
Figure 9: Arrest of Oct-6-deficient Schwann cells at the ensheathment stage (adapted from 
Bermingham et al., 1996). Oct-6 expression is transient  and precedes the peak of Krox-20 (Egr2), 
Mag, Mbp, and Mpz expression. Pax3 expression declines prior to the onset of myelination (SC: 
Schwann cell; A: axon). 
 
The closely related proteins Brn-1 and Brn-2, which belong to the same class (class III) of POU-
proteins as Oct-6, are able to compensate for the loss of Oct-6. Brn-1, which is usually not expressed 
in Schwann cells, can fully replace Oct-6, when manipulated to be expressed instead of Oct-6 (Brn-1 
knockin; Friedrich et al., 2005). Brn-2 is expressed in Schwann cells at the same time as Oct-6, but has 
only partially overlapping functions. One reason for this might be that Oct-6 and Brn-2 require 
different co-factors, members of the Sry-box containing transcription factors, Sox10 and Sox11, 
respectively, for full transcriptional activity (Jaegle et al., 2003).  
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Both, activating as well as repressing transcriptional effects, have been attributed to Oct-6 in the 
course of Schwann cell development. In Oct-6-deficient animals, expression of Egr2 and of the myelin 
genes (Mpz and Mbp) was reduced. The effect on the latter two might be indirect, since both genes are 
also dependent on Egr2. Conditional transgenic mice that constitutively express Oct-6 specifically in 
Schwann cells (condPou3f1:Mpz(Cre); Ryu et al., 2007) show a persistent block in myelination. These 
mice have normal levels of Egr2, but the levels of Mpz, Mbp, and Pmp22 are significantly reduced. 
Taken together the results argue for the following scenario: Oct-6 exerts activating (Egr2) as well as 
repressing (Mpz, Mbp, Pmp22) functions during myelination. Correctly timed expression of Oct-6 is 
crucial for the terminal differentiation of myelinating Schwann cells.  
 
Other roles of Oct-6 
Apart from its crucial role in Schwann cell development, Oct-6 is involved in the terminal 
differentiation of keratinocytes. Together with another POU-family member, Skn1a (Pou2f3, Oct-11), 
Oct-6 exerts repressive effects on the expression of keratin K14 (Andersen et al., 1997; Sugihara et al., 
2001) and matrix metalloprotease 19 (Beck et al., 2007). Moreover, Oct-6 is also expressed in 
pancreatic β-cells, where it activates the expression of Sst1, a gene encoding somatostatin receptor 1 
(Baumeister and Meyerhof, 2000).  
 
POU-proteins in the immune system 
Some POU-proteins play a role in the immune system. For example, Oct-2 and in a redundant way 
Oct-1, regulate immunoglobuline gene expression in B-cells (Phillips and Luisi, 2000). Oct-1 binding 
sites have been identified within the promoters of several IFNα subtypes and in Oct-1-deficient 
murine embryonic fibroblasts IFNα expression was enhanced (Mesplède et al., 2005). Similarly, a 
functional Oct-1 binding site has been reported within the human IFNβ promoter, and IFNβ 
expression can be repressed by Oct-1 (Haggarty et al., 1991). Several POU-transcription factors (Oct-
1, Oct-2, Brn3a and Brn3b) have activating effects on inducible nitric oxide synthase (iNOS). In 
addition to the NFκB, C/EBPβ, ISRE and Irf1 sites, an octamer consensus motif is located 
approximately 60 bp upstream of the iNOS transcription start site (Goldring et al., 1996; Kleinert et 
al., 2004). A role for Oct-6 in the context of immunity has not been described so far. 
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AIMS  
 
The first aim of the thesis is to elucidate the role of Tyk2 during LPS responses in macrophages using 
transcriptional-profiling approach. In a whole genome microarray experiment the transcriptional 
responses of WT and Tyk2-deficient peritoneal macrophages to LPS will be compared. Expression 
levels of genes found to be differentially regulated in the absence of Tyk2 will be further analysed 
using RT-qPCR.  
 
The second aim is based on previous findings that Oct-6 is induced in response to IFNβ treatment in a 
Tyk2-dependent manner. Oct-6 expression patterns in response to IFNs, other cytokines and in the 
course of viral infections will be analysed in detail on mRNA as well as on protein level. Moreover, 
the molecular requirements for Oct-6 induction, i.e. signalling molecules, transcription factors and cis-
regulatory elements, will be analysed. Finally, the question, whether Oct-6 is involved in 
transcriptional regulation in the context of innate immunity, will be addressed in gain- and loss-of-
function experiments.  
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MATERI ALS and  METHODS  
 
Mice  
Wild type mice (C57BL/6) and mice deficient for Ifnar1 (Muller et al., 1994), Tyk2 (Karaghiosoff et 
al., 2000), Stat1 (Durbin et al.,1996), Irf1 (Reis et al., 1994) and IFNβ (Erlandsson et al., 1998) (all 
C57BL/6 background) were housed under specific pathogen-free conditions. Oct-6 heterozygous mice 
(mixed background) were a kind gift of Dies Meijer (Department of Cell Biology and Genetics, 
Erasmus University Medical Center Rotterdam, Netherlands; Jaegle et al., 1996), the heterozygous 
breeding was done under conventional housing. Genotyping of Oct-6-/- mice and cells was done by 2 
PCRs, one for Oct-6 (across the inserted Neo-cassette) and one for the Neo-cassette (Figure 10). The 
PCRs were run in a final volume of 25 µl containing 300 nM primer (gtOct6-F: CCAACCTGG-
ACAAGATCG, gtOct6-R: CGCATAAACGTCGTCCAT, gtNeo-F: TTTTGTCAAGACCGACCTG, 
gtNeo-R: TGATGGATACTTTCTCGGC), 200 µM dNTP mix, 1x Biotaq buffer, 1U/reaction Biotaq 
DNA polymerase. MgCl2 was used at a final concentration of 2 mM and 1.5 mM for the Oct-6- and 
the Neo-PCR, respectively. For the Oct-6 amplification 5% of DMSO was added. The Oct-6 PCR was 
run under the following conditions: 5 min initial denaturation at 95°C, 40 cycles of 95°C for 30 sec, 
54°C for 30 sec and 72°C for 30 sec. The PCR for the Neo-cassette was run under following 
conditions: 5 min initial denaturation at 95°C, 40 cycles of 95°C for 30 sec, 55°C for 20 sec and 72°C 
for 30 sec. 
 
 
 
Figure 10: Targeted disruption of Oct-6 (adapted from Jaegle et al., 1996). The thick black line 
indicates the transcribed part of the Oct-6 locus, which is encoded by a single exon on mouse 
chromosome 4. The open box represents the open reading frame, the hatched box shows the part of the 
POU-domain. A β-galactosidase-neomycin (lacZ-Neo) fusion gene under the control of an internal 
ribosome entry site (IRES) was inserted into the XhoI site of the Oct-6 gene, thereby disrupting the 
DNA-binding domain of the Oct-6 protein. From the mutant allele a 6.9 kb bicistronic mRNA is 
expressed, no full-length Oct-6 protein can be produced from this mRNA.  
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Cell culture  
Bone marrow-derived macrophages (BMMs) were grown by culturing bone marrow cells in DMEM 
(high glucose; Invitrogen) supplemented with 15% L929 cell line conditioned medium (Baccarini et 
al., 1985), 10% fetal calf serum (FCS; Invitrogen), 2 mM L-glutamin (L-Glu; Invitrogen), 100 µg/ml 
penicillin and 100 U/ml streptomycin (Pen/Strep; Invitrogen) and 50 µM β-mercaptoethanol (β-ME; 
Invitrogen). Fully differentiated macrophages were used for experiments on day 7 after isolation. Fetal 
liver-derived macrophages (FLMs) were derived by culturing suspensions of fetal livers (d 13.5-14.5) 
under the same conditions like BMMs. FLMs were used for experiments on d 6 after isolation. For 
peritoneal macrophages (PMs, Bogdan et al., 1997), mice were injected with 2 ml of 4% thioglycollate 
intra-peritoneally four days prior to isolation. PMs were prepared by peritoneal lavage and cultivated 
for 1 day prior to the experiment in DMEM containing 5% FCS, L-Glu, Pen/Strep and β-ME. Primary 
murine embryonic fibroblasts (pMEFs) were derived by homogenisation of decapitated fetuses  
(d 13.5-14.5) after removal of the liver. Primary MEFs were grown in DMEM supplemented with 10% 
FCS, L-Glu, Pen/Strep and β-ME. For cultivation of MEF cell lines the same medium but without  
β-ME was used. SW10 cells, a murine, SV40 large T-antigen-immortalised Schwann cell line 
(purchased from ATCC®; Catalog No. CRL-2766; Hai et al., 2002), were grown in DMEM 
supplemented with 10% FCS, L-Glu, and Pen/Strep at the permissive temperature of 33°C. For 
experiments, cells were shifted to 37°C and/or 39°C in order to inactivate the temperature-sensitive 
SV40 large T-antigen.  
 
Treatments and infections 
Cells were treated for the indicated time points with indicated amounts of IFNα, IFNβ, IFNγ or IL-6 
(all purchased from Calbiochem), with polyinosinic-polycytidylic acid (poly(I:C), GE Healthcare) or 
lipopolysaccharide (LPS, E. coli serotype O55:B5, Sigma). Primary MEFs were transfected with 
poly(I:C) according to the manufacturer’s protocols (MEF1 nucleofector kit, AMAXA transfection 
system). For infection of cells with murine cytomegalovirus (MCMV) a standard multiplicity of  
infection (MOI) of 1 was used. For optimal infection efficiency, cells were centrifuged at 3000 rpm 
(Beckman GH3.8A rotor; equals 1462 rcf on average, or 2056 rcf on maximum) for 30 min.  
 
Plaque assays 
Supernatants of infected cells were collected at indicated times and titrated onto a Stat1-deficient MEF 
cell line. Therefore, 2.5 x 105 MEFs per well were plated into 24-well plates and covered with serial 
10-fold dilutions of the supernatant. Cells were incubated at 37°C for 1 to 2 hours with gently rocking 
the plates every 15 minutes. Virus containing medium was removed and replaced by fresh medium 
containing 1% agarose. Cells were incubated until plaques could be counted, usually 4 to 5 days after 
infection.  
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Plasmids and overexpression 
Expression plasmids (CMV-enhancer driven based on pEVRF0 plasmid; Meijer et al., 1992 and 
references therein) of Oct-6, Brn-1 and Brn-2 were kindly provided by Dies Meijer (Department of 
Cell Biology and Genetics, Erasmus University Medical Center Rotterdam). Additionally, we cloned 
the sense as well as the antisense sequence of the Oct-6 cDNA, and the sense sequence of Oct-1 
cDNA, into the EF1α-promoter driven expression vector pEFZeo (kind gift of Pavel Kovarik, MFPL 
University, Vienna). Oct-6 coding sequence (cds) was PCR-amplified from genomic DNA with 
primers containing restriction sites for BamHI (underlined) at the 5’ends of the forward 
(Oct6_BamHI-F: TACGGATCCCGCAGACGGAGCGAGGCG) and reverse (Oct6_BamHI-R: 
TAGGGATCCGAACCCAGTCCGCAGGGTCAC) primer under the following conditions: in 50 µl 
final volume 300 nM primer (Invitrogen), 5% DMSO (Sigma), 200 µM dNTPs, 5 U/reaction Pfu DNA 
polymerase, 1x Pfu buffer incl. MgSO4 (2 mM final concentration; all MBI Fermentas) were used, 
running following PCR program: 95°C for 3 min, 35 cycles of 95°C for 30 sec, 67°C for 30 sec, 72°C 
for 2 min, and a final extension step of 72°C for 7 min. The pEFZeo plasmid was digested with 
EcoRV and the 1.4kb column purified insert was blunt-ligated into the vector. Sense and antisense 
insertion was checked by XhoI digestion.  
For Oct-1 cds amplification, cDNA was prepared using the iScript Select first strand cDNA synthesis 
kit with oligo(dT)20 priming (Biorad). PCR for Oct-1 cds with primers containing restriction sites for 
BamHI and XbaI at the 5’ends of the forward (Oct1_BamHI-F: TACGGATCCAGCAGCAGA-
CTCAAGAATGAA) and reverse (Oct1_XbaI-R: TAGTCTAGAGTAGTGAGGAAAGCCTGTGGC) 
primer, respectively, was done under following conditions: 300 nM primer (Invitrogen), 200 µM 
dNTPs, 5 U/reaction Pfu DNA polymerase, 1x Pfu buffer incl. MgSO4 (2 mM final concentration; all 
MBI Fermentas), running following PCR program: 95°C for 3 min, 5 cycles of 95°C for 30 sec, 55°C 
for 30 sec, 72°C for 3 min, followed by 35 cycles of 95°C for 30 sec, 65°C for 30 sec, 72°C for 3 min 
and a final extension step of 72°C for 7 min. The 2.3kb fragment was cut and purified from the gel as 
described above. The pEFZeo plasmid was double digested with BamHI and XbaI (MBI Fermentas), 
dephosphorylated (CIAP; MBI Fermentas) and column-purified (Qiaquick protocol; Qiagen). The 
PCR product was also double digested and column-purified and ligated into the pEFZeo plasmid. 
Insertion was checked by BamHI/XbaI double digestion. The enhanced GFP expression plasmid 
(GFP) was supplied with the transfection kit (AMAXA Lonza) as a positive control.  
For amplification plasmids were transfected into CaCl2-competent E. coli XL-1 blue following a 
heatshock transformation protocol. Amplified plasmids were purified using the Jetstar Plasmid 
Midiprep 2.0 Kit (Genomed). Plasmid transfection into pMEFs (10 µg DNA/2x106 cells) was 
performed using the AMAXA nucleofector system (MEF1 nucleofector kit) according to the 
manufacturer’s instructions. 
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Whole-cell extracts, SDS-polyacrylamid-gelelectrophoresis and western blot  
Cells were lysed in a buffer containing 50 mM Tris.HCl pH8, 150 mM NaCl, 0.5% Nonidet P-40, 10% 
glycerol, 2 mM DTT, 0.1 mM EDTA, 0.2 mM Na3VO4, 25 mM NaF, 1 µg/ml aprotinin, 1 µg/ml 
leupeptin and 1 mM PMSF. In order to remove cell debris, samples were centrifuged at 20.800 x g for 
8 minutes at 4°C. Whole-cell lysates were mixed 1:1 with 2x Lämmli sample buffer (126 mM 
Tris.HCl pH6.8, 4% SDS, 20% glycerol, 0.02% bromphenolblue, 200 mM DTT), denaturated at 96°C 
for 10 minutes and separated on 6.5%, or 8% polyacrylamide-gels, containing 0.01% SDS (10x 
electrode buffer without SDS: 1L contains 144 g glycin and 30 g Tris.base; 1 x buffer contains 0.01% 
SDS). The gels were blotted (1x transfer buffer: 25 mM Tris.base, 150 mM glycine, 20% methanol) 
onto nitrocelullose membranes (GE Healthcare) which were then blocked in a 5% milk powder 
solution (ressolved in 1x PY-TBST: 100 mM Tris.HCl pH 7.4, 750 mM NaCl, 1 mM EDTA, 0.1% 
Tween-20). The membranes were probed with the indicated primary antibodies. For detection  
α-rabbit-IgG, or α-mouse-IgG horse-radish peroxidase conjugated secondary antibodies were used 
(table 3). Target bands were visualised by a chemiluminescence reaction using the ECLTM-detection 
system (GE Healthcare) according to the manufacturer’s instructions.  
 
Table 3: Antibodies for western blot (WB), supershift (SS), immunoprecipitation (IP), and 
immunofluorescence (IF) 
Antibody origin Application (dilution) from  Cat. number 
primary antibodies  
α-Oct-6 (N-terminal) rabbit  WB (1:1000) Dies Meijer1 - 
α-Oct-6 (C-terminal) goat IF (1:50); SS, IP Santa Cruz sc-11661 
α-Oct-1 (12F11) X mouse SS Santa Cruz  sc-8024 X 
α-Oct-2 (C-20) X rabbit SS Santa Cruz sc-233 X 
α-Stat1-C rabbit IP Pavel Kovarik2 - 
α-phospho-NFκB p65 
(Ser536) mouse 1:1000 
Cell Signaling 
Technology 3036 
α-NFκB p65 rabbit WB (1:1000) Upstate Cell Signaling solutions 06-418 
α-phospho-p38 
MAPK 
(Thr180/Tyr182) 
rabbit WB (1:1000) Cell Signaling Technology 9211 
α-p38 MAPK rabbit WB (1:1000) Cell Signaling Technology sc-535 
α-pan-Erk mouse WB (1:2000) BD Biosciences 612641 
secondary antibodies  
α-rabbit IgG donkey WB (1:2000) GE Healthcare NA9340 
α-mouse IgG sheep WB (1:2000) GE Healthcare NA9310 
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Antibody origin Application (dilution) from  Cat. number 
α-goat IgG donkey WB (1:20000) Jackson ImmunoResearch Labs 705-035-003 
α-goat IgG-Fluor488 rabbit IF (1:200) Alexa a-21222 
Primary antibodies for WB were diluted in 1% BSA, 0.01% azide (in PY-TBST). 
Secondary antibodies for WB diluted in 1% milk (in PY-TBST). 
1 (Zwart et al., 1996), 2 (Kovarik et al., 1998) 
 
Immunoprecipitation  
Whole cell lysates (1 mg/ml protein in the lysis buffer described above) were incubated with 2 µg 
antibody (table 3) rotating at 4°C overnight. Protein-A sepharose CL-4B (Pharmacia Biotech; in case 
the antibody origin was rabbit) or Protein-G PLUS-agarose (Santa Cruz; in case the antibody origin 
was goat) was added (50 µl of 50% slurry) and samples were incubated rotating for another 2 hours at 
4°C. After washing, beads were resuspended in 50 µl 2x Lämmli sample buffer and submitted to 
western blot analysis as described above.  
 
Electrophoretic mobility shift assays (EMSAs, bandshifts) 
The sense oligonucletide (200 ng; OCT-probe: GAGAGGAATTTGCATTTCCACCGACCTTCC, 
Invitrogen; c-abl; Jaegle et al., 2003) was radioactively labelled at the 5’end using a T4 polynucleotide 
kinase reaction (MBI Fermentas) according to the manufacturer’s instructions. Labelled sense and the 
antisense oligonucleotide were annealed by adding 250 ng of the antisense oligonucleotide to the 
labelling reaction mix, inreasing the NaCl concentration (by adding 1.5 µl of an 1.5 M NaCl solution), 
heating the mixture to 95°C for 5 min and slowly cooling to room temperature. The radioactive 
dsDNA oligonucleotide was purified via NAPTM-5 G25 sepharose columns (area: 0.9 x 2.8 cm; 
Pharmacia) and 10 fractions à 100 µl were collected. The fraction containing the dsDNA 
oligonucleotide (usually fraction 5-6) was used for bandshift experiments. Whole-cell extracts (10 to 
15 µg/15µl) were incubated with 2 µl poly(dI:dC) (62.5 U/ml; Amersham) for 5 min at room 
temperature. A probe mix (for 20 samples including 10% volume for pipet lost) was prepared 
containing 100 µl WBB (1x; Wu-Binding-Buffer: 10 mM HEPES, 1.5 mM MgCl2, 0.1 mM EGTA, 
5% glycerol, 100 nM NaCl), 100 µl Ficoll (10% in 1x WBB), 10 µl BSA (50 µg/µl; fraction V, 
Sigma), 10 µl tRNA (10 µg/µl; from baker’s yeast, Sigma) and radioactively labelled dsDNA probe (8 
µl). After incubation with poly(dI:dC) 10 µl of probemix were added and samples were incubated at 
room temperature for 20 min. 25 µl/sample were separated on a 6% polyacrylamide gel (in 0.5x Tris-
borate-EDTA buffer) under native conditions for 3 hours with 200 V. Bandshifts were detected by 
autoradiography. Supershifts were done by incubating the cell extracts with 1 µl of the respective 
antibody (α-Oct-6, α-Oct-1, α-Oct-2; all Santa Cruz, table 3) prior to separation.  
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Immunofluorescence 
Cells (7.5 x 105 FLMs, BMMs) were grown and stimulated on glass slides, and fixed with 4% 
formaldehyde for 15 minutes (Histofix, Roth). Formaldehyde was quenched by glycine (100 mM, 15 
minutes), cells were permeabilised by methanol treatment (-20°C, 5 minutes). Slides were blocked 
with 1% BSA in PBS for 1 hour. Oct-6 was detected incubating the slides with α-Oct-6 primary 
antibody (Santa Cruz; 1:50 in blocking solution from a 0.2 mg/ml stock solution; 4°C overnight) and a 
fluorescently labelled α-goat IgG secondary antibody (Fluor 488; Alexa; 1:200 in PBS; 1 hour at room 
temperature in the dark). In order to control for unspecific signals, goat IgG (Invitrogen Cat. No. 02-
6202; 1:50 in blocking solution from 0.5 µg/ml solution) was used as an isotype control instead of the 
specific primary antibody.  
 
Chromatin immunoprecipitation (ChIP) 
ChIP for Stat1 (α-Stat1-C) was performed as described earlier (Nissen and Yamamoto, 2000; Sadzak 
et al., 2008) with minor modifications. Sonication (Sonopuls HD70, MS72 sonotrode; Bandelin) was 
initially performed at 50% power and only 30% duty cycle in order to avoid foaming, for 10 times 15 
sec with 1 min break between the pulses. This procedure was then repeated with the duty cycle 
increased to 90%. Equal amounts of lysate were used for Stat1 immunopreciptation (4 µl α-Stat1-C 
antibody/500 µl lysate; the antibody was a kind gift of Pavel Kovarik, MFPL University, Vienna) and 
a control reaction using unspecific rabbit serum. DNA was isolated following a phenol:chloroform 
extraction protocol and subjected to PCR analysis. PCRs were run in a final volume of 25 µl 
containing 300 nM primer (ChIP_Oct6-F: GTCTCTGCTCGGAACCCGA, ChIP_Oct6_S-R: 
CCCACGTTCCACACAAGCT, ChIP_Oct6_L-R: GCCCGCGTACACATTCAC; ChIP_Irf1-F: 
GCACAGCTGCCTTGTACT-TCC, ChIP_Irf1-R: TCGGCCTCATCATTTCGG), 2 mM MgCl2, 200 
µM dNTP mix, 1x Biotaq buffer, 2 U/reaction Biotaq DNA polymerase under these cycling 
conditions: 5 min at 95°C for initial denaturation, followed by 35 cycles of  95°C for 30 sec and 61°C 
for 1 min. PCRs were done from all samples of the α-Stat1 IP, the control IP (unspecific rabbit serum; 
Sigma) and from an aliquot of the initial sample input prior to the IP (input DNA).  
 
RNA isolation and reverse transcription 
Total RNA was isolated following the TRiZOL (Invitrogen) protocol. RNA concentration and purity 
was assessed by photometric analysis, measuring the absorption (A) at 260 nm and 280 nm for nucleic 
acids and protein contamination, respectively. RNA was considered to be pure when the ratio of 
A260/A280 was about 2.0. RNA integrity was further analysed by gel electrophoresis under non-
denaturing conditions. Prior to cDNA synthesis the RNA was treated with 1 U/µg RNA RQ1 DNase I 
(Promega) in order to digest contaminating genomic DNA. Then cDNA was prepared from 1 µg total 
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RNA using the iScript First Strand cDNA synthesis kit (Biorad), always including controls for DNA 
contamination, that were prepared lacking the reverse transcriptase (RT- controls).  
 
Real-time quantitative PCR (qPCR) analysis of gene expression  
Target gene expression was assessed by qPCR with Ube2d2 as endogenous control gene. Taqman® 
probes labelled with 6-carboxyfluorescein (FAM) at the 5’end, and a black-hole-quencher (BHQ1) at 
the 3’end were used to quantify IFNβ and Ube2d2 (table 4). For the quantification of IL17-A and 
IL17-F, ready-to-use Taqman® assays were purchased from Applied Biosystems (IL17-A: 
Mm00439619_m1, IL17-F: Mm00521423_m1). The dsDNA-binding dye EvaGreen (Biotium) was 
chosen to detect Oct-6, Egr2, Pmp22 and the genes that were to be validated from the microarray 
(Dapp1, Dyrk1b, E4f1, Lsm10, Map3k5, Map3k12, Nox1, Stk40, and Zdhhc3; table 5).  
 
Table 4: qPCR assays using Taqman® probes (continued on the following page).  
gene oligo-name oligo-sequence 
Ube2d2 
Ubiquitin conjugating 
enzyme E2D 2 
Ube2d2-F AGGTCCTGTTGGAGATGATATGTT 
Ube2d2-R TTGGGAAATGAATTGTCAAGAAA 
Ube2d2-FAM CCAAATGACAGCCCCTATCAGGGTGG 
IFNβ 
Interferon beta 1, 
fibroblast 
IFNβ-F ATGAGTGGTGGTTGCAGGC 
IFNβ-R TGACCTTTCAAATGCAGTAGATTCA 
IFNβ-FAM AAGCATCAGAGGCGGACTCTGGGA 
panIFNα 
Interferon alpha 1-14 
panIFNα-F CCACAGGATCACTGTGT(A/T)CCTGAGA
panIFNα-R CTGATCACCTCCCAGGCACAG 
panIFNα-FAM1 AG+AA+GAA+A+C+AC+AG+CC 
iNOS 
Inducible nitric oxide 
synthase 
iNOS-F TGGTCCGCAAGAGAGTGCT 
iNOS-R CCTCATTGGCCAGCTGCTT  
iNOS-FAM CCCGGCAAACCCAAGGTCTACGTTC  
1 Locked nucleic acids (LNAs) containing probe: LNA monomers are indicated by the “+” in front  
  of the respective bases (Letertre et al., 2003).  
 
 
Table 5: qPCR assays using a dsDNA-binding dye (EvaGreen).  
gene oligo-name oligo-sequence 
Oct-6 
POU domain, class 3, transcription 
factor 1 
Oct-6-F AGGTCCTGTTGGAGATGATATGTT
Oct-6-R TTGGGAAATGAATTGTCAAGAAA 
Egr2 
early growth response 2 
Egr2-F GGTGACCATCTTCCCCAATG 
Egr2-R TTGATCATGCCATCTCCCG 
Pmp22 
peripheral myelin protein 22 
Pmp22-F CCGGTTTTACATCACTGGATTCT 
Pmp22-R TGTAGATGGCCGCTGCACT 
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gene oligo-name oligo-sequence 
Dapp1 
dual adaptor for phospho-tyrosine and 
3-phospho-inositides 1 
Dapp1-F AAAGAAGGCTATCTCACCAAGCA 
Dapp1-R AGGTCTAGGATCCGAATTGGTTC 
Dyrk1b 
dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1b 
Dyrk1b-F CCATTGACATGTGGTCCCTG 
Dyrk1b-R TGCCCAACACCTCCACAATA 
E4f1 
E4F transcription factor 1 
E4f1-F GTGGAGTTCTCGTCTGTGGTAGCT 
E4f1-R CAATGATCTCGGTGGCTTCA 
Lsm10 
U7 snRNP-specific Sm-like protein 
LSM10 
Lsm10-F CCTCCAAAAGGCCATGAGACT 
Lsm10-R CGGGAGTTGGCTCAGAACAC 
Map3k5 
mitogen-activated protein kinase 
kinase kinase 5 
Map3k5-F TCCGATTCACTCCAGTCCCT 
Map3k5-R TCACAGCAGTAGACCTTGTTGTGT 
Map3k12 
mitogen-activated protein kinase 
kinase kinase 12 
Map3k12-F GTCTGGACAATGATTGGCAAAG 
Map3k12-R GAAGCGTCCCAGGAAAACAG 
Nox1 
NADPH oxidase 1 
Nox1-F GGGAGACCAATGTGGGACAA 
Nox1-R CTCGAGTATCGCTGACAGCG 
Stk40 
serine/threonine kinase 40 
Stk40-F CTCTCAGTGCCATCATTGCATC 
Stk40-R CACCTTTGCCTCCTGGGA 
Zdhhc3 
zinc finger, DHHC domain 
containing 3 
Zdhhc3-F TCCTTGCACGCCCTCATC 
Zdhhc3-R GGCGAGAAGGAGCTGCACT 
 
Taqman qPCR assays were run in a final volume of 25 µl containing 300 nM primer (Invitrogen),  
100 nM probe (Sigma or Metabion), 200 µM dNTP mix (Fermentas), 4 mM MgCl2, 1x HotFire buffer 
B, and 1U/reaction HotFire DNA polymerase (all Solis BioDyne). The conditions were basically the 
same for the EvaGreen assays except for the use of 0.2x EvaGreen dye instead of the probe in the 
presence of only 2.5 mM MgCl2. All qPCRs were run on a Mastercycler® ep Realplex (Eppendorf) 
applying following cycling conditions: 15 min at 95°C for initial denaturation, then 40 to 45 cycles of 
95°C for 20 sec and 60°C for 1 min. In case of the EvaGreen-assays, the PCR was followed by a 
melting curve analysis in order to confirm assay specificity.  
Data were analysed using the realplex software (Eppendorf) and relative target gene expression levels 
(i.e. n-fold expression levels) were calculated following the standard curve method (Giulietti et al., 
2001; Karaghiosoff et al., 2003), or following the ΔΔCt method, assuming an amplification efficiency 
of 100% (Bustin, 2000).  
 
Gene expression profiling using Taqman® Custom Arrays 
Taqman® Custom Arrays (Applied Biosystems) were used to analyse the expression of 240 genes in 
PMs upon LPS treatment. These medium-throughput arrays are 384-well micro fluidic cards and 
available in several conformations. We used 1 array in the 48-genes-format allowing the analysis of 48 
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genes for 4 samples in duplicates in one run. Two more arrays in the 96-genes-format were run, 
analysing 96 genes for 4 samples in unicates per run (table 6). RNA (50 ng/µl) was reverse transcribed 
using the iScript First Strand cDNA Synthesis Kit (Biorad). For qPCR a 100 µl mastermix was loaded 
per sample-loading port including 250 ng cDNA (assumed to equal RNA input). The mastermix 
further contained 200 µM of each dNTP (MBI Fermentas), 1 x ROX reference dye (Invitrogen), 5 mM 
MgCl2, 1 x reaction buffer B and 4 U HotFire DNA polymerase (all Solis Biodyne). The arrays were 
processed as described by the manufacturer’s protocol. QPCR was performed on the ABI PRISM 
7900 HT (Applied Biosystems) running the following cycling conditions: initial denaturation at 95 °C 
for 12 min, 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Data were analysed using the SDS 2.2 
software (Applied Biosystems). 
 
Table 6: Gene list for the Taqman® low density arrays (continued on the following pages). 
 gene symbol gene name [commonly known alias] assay ID 
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Rn18s 18S rRNA 4342379 
Cpd carboxypeptidase D Mm00483956_m1 
Csf3 colony stimulating factor 3 (granulocyte) Mm00438334_m1 
Csnk1g1 casein kinase 1, gamma 1 Mm00557447_m1 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 [Rig-I] Mm00554529_m1 
Ddx6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 Mm00619326_m1 
Dhx29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 Mm00553691_m1 
Dhx9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 Mm00456021_m1 
Dnmt1 DNA methyltransferase (cytosine-5) 1 Mm00599763_m1 
Eda2r ectodysplasin A2 isoform receptor Mm00723601_m1 
Eef1a2 eukaryotic translation elongation factor 1 alpha 2 Mm00514649_m1 
Efnb2 ephrin B2 Mm00438670_m1 
Eif2c1 eukaryotic translation initiation factor 2C, 1 Mm00462977_m1 
Myof (Fer1l3) myoferlin Mm00621780_m1 
Fmr1 fragile X mental retardation syndrome 1 homolog Mm00484415_m1 
Gbp2 guanylate binding protein 2 Mm00494575_m1 
Grb10 growth factor receptor bound protein 10 Mm00494735_m1 
Hipk2 homeodomain interacting protein kinase 2 Mm00439329_m1 
Hmbs hydroxymethylbilane synthase Mm00660262_g1 
Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 Mm00446968_m1 
Ifi203 interferon activated gene 203 Mm00492597_m1 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 [Ifi56] Mm00515153_m1 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 [Ifi54] Mm00492606_m1 
Iqgap1 IQ motif containing GTPase activating protein 1 Mm00443860_m1 
Irf1 interferon regulatory factor 1 Mm00515191_m1 
Irf7 interferon regulatory factor 7 Mm00516788_m1 
Jak1 Janus kinase 1 Mm00600614_m1 
Mx1 myxovirus (influenza virus) resistance 1 Mm00487796_m1 
Notch3 Notch gene homolog 3 (Drosophila) Mm00435270_m1 
Oas1b 2'-5' oligoadenylate synthetase 1B Mm00449297_m1 
Pftk1 PFTAIRE protein kinase 1 Mm00448111_m1 
R3hdm1 R3H domain 1 (binds single-stranded nucleic acids) Mm00725197_m1 
Rhpn1 rhophilin, Rho GTPase binding protein 1 Mm00492435_m1 
Polr1a (Rpo14) polymerase (RNA) I polypeptide A Mm00485835_m1 
Rqcd1 rcd1 (required for cell differentiation) homolog 1 (S. pombe) Mm00457967_m1 
Sfrp1 secreted frizzled-related protein 1 Mm00489161_m1 
Skiv2l superkiller viralicidic activity 2-like (S. cerevisiae) Mm00451675_m1 
Smad3 MAD homolog 3 (Drosophila) Mm00489637_m1 
Smarcc1 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 
Mm00486224_m1 
Smc1a structural maintenance of chromosomes 1A Mm00490624_m1 
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Socs1 suppressor of cytokine signaling 1 Mm00782550_s1 
Srrm1 serine/arginine repetitive matrix 1 Mm00489728_m1 
Stat1 signal transducer and activator of transcription 1 Mm00439518_m1 
Sulf1 sulfatase 1 Mm00552283_m1 
Trim37 tripartite motif-containing 37 Mm00816034_s1 
Ube2d2 ubiquitin-conjugating enzyme E2D 2 Mm00785931_s1 
Ubtf upstream binding transcription factor, RNA polymerase I Mm00456972_m1 
Usp45 ubiquitin specific petidase 45 Mm00507696_m1 
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Rn18s 18S rRNA 4342379 
A2m alpha-2-macroglobulin Mm00558642_m1 
Als2 amyotrophic lateral sclerosis 2 (juvenile) homolog (human) Mm00511865_m1 
Arap3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 Mm00551866_m1 
Arhgef2 rho/rac guanine nucleotide exchange factor (GEF) 2 Mm00434757_m1 
As3mt arsenic (+3 oxidation state) methyltransferase Mm00491075_m1 
Bhmt2 betaine-homocysteine methyltransferase 2 Mm00517726_m1 
Xiap (Birc4) X-linked inhibitor of apoptosis Mm00776505_m1 
Casp2 caspase 2 Mm00432314_m1 
Cd3d CD3 antigen, delta polypeptide Mm00442746_m1 
Cd79a CD79A antigen (immunoglobulin-associated alpha) Mm00432423_m1 
Cd84 CD84 antigen Mm00488934_m1 
Cdkn1b cyclin-dependent kinase inhibitor 1B Mm00438168_m1 
Cidea cell death-inducing DNA fragmentation factor, alpha subunit-like 
effector A 
Mm00432554_m1 
Cpd carboxypeptidase D Mm00483956_m1 
Csnk1a1 casein kinase 1, alpha 1 Mm00521599_m1 
Dab2 disabled homolog 2 (Drosophila) Mm00517751_m1 
Dclre1a DNA cross-link repair 1A, PSO2 homolog (S. cerevisiae) Mm00457569_m1 
Dlx5 distal-less homeobox 5 Mm00438430_m1 
Dvl3 dishevelled 3, dsh homolog (Drosophila) Mm00432914_m1 
Dyrk1b dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1b Mm00599813_m1 
Ebf2 early B-cell factor 2 Mm00438622_m1 
Eef1e1 eukaryotic translation elongation factor 1 epsilon 1 Mm00470535_m1 
Egr3 early growth response 3 Mm00516979_m1 
Epha4 Eph receptor A4 Mm00433056_m1 
Ercc4 excision repair cross-complementing rodent repair deficiency, 
complementation group 4 
Mm00516619_m1 
Ercc5 excision repair cross-complementing rodent repair deficiency, 
complementation group 5 
Mm00468968_m1 
Esm1 endothelial cell-specific molecule 1 Mm00469953_m1 
Ets1 E26 avian leukemia oncogene 1, 5' domain Mm00468970_m1 
Evi2b ecotropic viral integration site 2b Mm00524622_m1 
Fgf1 fibroblast growth factor 1 Mm00438906_m1 
Fgf17 fibroblast growth factor 17 Mm00433282_m1 
Gabpb2 GA repeat binding protein, beta 2 Mm00552940_m1 
Gnao1 guanine nucleotide binding protein, alpha O Mm00494677_m1 
Gnaz guanine nucleotide binding protein, alpha z subunit Mm00726444_s1 
Hmbs hydroxymethylbilane synthase Mm00660262_g1 
Hoxc5 homeo box C5 Mm00433971_m1 
Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 Mm00446968_m1 
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A Mm00555764_m1 
Icam5 intercellular adhesion molecule 5, telencephalin Mm00492566_m1 
Ifna2 interferon alpha 2 Mm00833961_s1 
Il17c interleukin 17C Mm00521397_m1 
Il7 interleukin 7 Mm00434291_m1 
Jak2 Janus kinase 2 Mm00434561_m1 
Klf2 Kruppel-like factor 2 (lung) Mm00500486_g1 
Lbp lipopolysaccharide binding protein Mm00493139_m1 
Lect1 leukocyte cell derived chemotaxin 1 Mm00495291_m1 
Lefty2 left-right determination factor 2 Mm00774547_m1 
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Lpin2 lipin 2 Mm00522390_m1 
Muc13 (Ly64) mucin 13, epithelial transmembrane Mm00495397_m1 
Masp1 mannan-binding lectin serine peptidase 1 Mm00434830_m1 
Mcpt1 mast cell protease 1 Mm00656886_g1 
Mcpt2 mast cell protease 2 Mm00484932_m1 
Mcpt8 mast cell protease 8 Mm00484935_g1 
Mdm4 transformed mouse 3T3 cell double minute 4 Mm00484944_m1 
Mds1 myelodysplasia syndrome 1 homolog (human) Mm00491303_m1 
Mga MAX gene associated Mm00465485_m1 
Foxo4 (Mllt7) forkhead box O4 Mm00840140_g1 
Mmp13 matrix metallopeptidase 13 Mm00439491_m1 
Mybl1 myeloblastosis oncogene-like 1 Mm00485327_m1 
Nat1 N-acetyltransferase 1 (arylamine N-acetyltransferase) Mm00500740_s1 
Nedd4 neural precursor cell expressed, developmentally down-regulated 4 Mm00456829_m1 
Nog noggin Mm00476456_s1 
Nrarp Notch-regulated ankyrin repeat protein Mm00482529_s1 
NULL unknown Mm00498572_m1 
Orm2 orosomucoid 2 Mm00440570_g1 
Padi4 peptidyl arginine deiminase, type IV Mm00478087_m1 
Pax3 paired box gene 3 Mm00435491_m1 
Pcsk2 proprotein convertase subtilisin/kexin type 2 Mm00500981_m1 
Pdcd1 programmed cell death 1 Mm00435532_m1 
Pou1f1 (Pit1) POU domain, class 1, transcription factor 1 (Pit1, growth hormone 
factor 1) 
Mm00476852_m1 
Pou3f1 POU domain, class 3, transcription factor 1 (Oct-6) Mm00843534_s1 
Ppp1r16b protein phosphatase 1, regulatory (inhibitor) subunit 16B Mm00462096_m1 
Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B Mm00454892_m1 
Prkce protein kinase C, epsilon Mm00440894_m1 
Prkcq protein kinase C, theta Mm00435796_m1 
Klk6 (Prss18) kallikrein related-peptidase 6 Mm00478322_m1 
Ptpn14 protein tyrosine phosphatase, non-receptor type 14 Mm00501215_m1 
Ptprm protein tyrosine phosphatase, receptor type, M Mm00436095_m1 
Ptprs protein tyrosine phosphatase, receptor type, S Mm00465158_m1 
Rb1 retinoblastoma 1 Mm00485586_m1 
Reck reversion-inducing-cysteine-rich protein with kazal motifs Mm00443829_m1 
Rgs6 regulator of G-protein signaling 6 Mm00658736_m1 
Runx2 runt related transcription factor 2 Mm00501578_m1 
Sf3a1 splicing factor 3a, subunit 1 Mm00660438_m1 
Slfn8 schlafen 8 Mm00824405_m1 
Socs2 suppressor of cytokine signaling 2 Mm00850544_g1 
Styxl1 serine/threonine/tyrosine interacting-like 1 Mm00472555_m1 
Supt6h suppressor of Ty 6 homolog (S. cerevisiae) Mm00486479_m1 
Tal1 T-cell acute lymphocytic leukemia 1 Mm00441665_m1 
Tbx4 T-box 4 Mm00550370_m1 
Tcea2 transcription elongation factor A (SII), 2 Mm00447447_m1 
Tcl1b5 T-cell leukemia/lymphoma 1B, 5 Mm00834432_g1 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 [Trail] Mm00437174_m1 
Traf1 TNF receptor-associated factor 1 Mm00493827_m1 
Ube2d2 ubiquitin-conjugating enzyme E2D 2 Mm00785931_s1 
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Rn18s 18S rRNA 4342379 
4932417H02Rik RIKEN cDNA 4932417H02 gene [Raptor] Mm00712676_m1 
Adipoq (Acdc) adiponectin, C1Q and collagen domain containing Mm00456425_m1 
Aif1 allograft inflammatory factor 1 Mm00479862_g1 
Aqp9 aquaporin 9 Mm00508094_m1 
Arg2 arginase type II Mm00477592_m1 
Bcar3 breast cancer anti-estrogen resistance 3 Mm00600213_m1 
Naip2 (Birc1b) NLR family, apoptosis inhibitory protein 2 Mm00440446_m1 
Nod2 (Card15) nucleotide-binding oligomerization domain containing 2 Mm00467543_m1 
Ccl5 chemokine (C-C motif) ligand 5  [RANTES] Mm01302428_m1 
Ccnb1 cyclin B1 Mm00838401_g1 
Nlrp3 (Cias1) NLR family, pyrin domain containing 3 Mm00840904_m1 
Cxcl9 chemokine (C-X-C motif) ligand 9 [Mig] Mm00434946_m1 
Cyp2c37 cytochrome P450, family 2. subfamily c, polypeptide 37 Mm00833845_m1 
Ddx50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 Mm00459758_m1 
Defb6 defensin beta 6 Mm00651498_m1 
Defa4 (Defcr4) defensin, alpha, 4 Mm00651736_g1 
Defa5 (Defcr5) defensin, alpha, 5 Mm00651548_g1 
Diras1 DIRAS family, GTP-binding RAS-like 1 Mm00507471_s1 
Dmrta1 doublesex and mab-3 related transcription factor like family A1 Mm00558696_m1 
Dok5 docking protein 5 Mm00499684_m1 
Dusp16 dual specificity phosphatase 16 Mm00459935_m1 
Ebi3 Epstein-Barr virus induced gene 3 Mm00469294_m1 
Faim2 Fas apoptotic inhibitory molecule 2 Mm00511461_m1 
Fgfr3 fibroblast growth factor receptor 3 Mm00433294_m1 
Fgr Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog [Mus 
musculus] 
Mm00438949_m1 
Fosb FBJ osteosarcoma oncogene B Mm00500401_m1 
Foxf1a forkhead box F1a Mm00487497_m1 
Foxj2 forkhead box J2 Mm00491502_m1 
Foxp3 forkhead box P3 Mm00475156_m1 
Gdf5 growth differentiation factor 5 Mm00433564_m1 
Gfi1 growth factor independent 1 Mm00515853_m1 
Ghrl ghrelin Mm00445450_m1 
Gimap9 GTPase, IMAP family member 9 Mm00558102_m1 
Gnas GNAS (guanine nucleotide binding protein, alpha stimulating) complex 
locus 
Mm00456660_m1 
Gnmt glycine N-methyltransferase Mm00494689_m1 
Prokr2 
(Gpr73l1) 
prokineticin receptor 2 Mm00769571_m1 
Hhex hematopoietically expressed homeobox Mm00433954_m1 
Hist1h1e histone cluster 1, H1e Mm00469312_s1 
Hmbs hydroxymethylbilane synthase Mm00660262_g1 
Hprt1 hypoxanthine guanine phosphoribosyl transferase 1 Mm00446968_m1 
Icam2 intercellular adhesion molecule 2 Mm00494862_m1 
Icam4 intercellular adhesion molecule 4, Landsteiner-Wiener blood group Mm00470225_g1 
Irf8 (Icsbp1) interferon regulatory factor 8 Mm00492567_m1 
Ifna4 interferon alpha 4 Mm00833969_s1 
Igsf9 immunoglobulin superfamily, member 9 Mm00459672_m1 
Il16 interleukin 16 Mm00516039_m1 
Il17b interleukin 17B Mm00444686_m1 
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Il17f interleukin 17F Mm00521423_m1 
Il2ra interleukin 2 receptor, alpha chain Mm00434261_m1 
Il9 interleukin 9 Mm00434305_m1 
Itgb3 integrin beta 3 Mm00443980_m1 
Khdrbs1 KH domain containing, RNA binding, signal transduction associated 1 Mm00516130_m1 
Lag3 lymphocyte-activation gene 3 Mm00493071_m1 
Lhx5 LIM homeobox protein 5 Mm00521778_m1 
Madd MAP-kinase activating death domain Mm00523709_m1 
Map3k6 mitogen-activated protein kinase kinase kinase 6 Mm00522222_m1 
Map3k8 mitogen-activated protein kinase kinase kinase 8 Mm00432637_m1 
Mitf microphthalmia-associated transcription factor Mm00434954_m1 
Msh2 mutS homolog 2 (E. coli) Mm00500563_m1 
Nfe2l3 nuclear factor, erythroid derived 2, like 3 Mm00477788_m1 
Nfkbib nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, beta 
Mm00456849_m1 
Nr2f6 nuclear receptor subfamily 2, group F, member 6 Mm00438762_m1 
Nxf2 nuclear RNA export factor 2 Mm00453239_m1 
Palm2 paralemmin 2 Mm00556267_m1 
Pdcd1lg2 programmed cell death 1 ligand 2 Mm00451734_m1 
Phkg1 phosphorylase kinase gamma 1 Mm00440767_m1 
Pla2g10 phospholipase A2, group X Mm00449530_m1 
Plunc palate, lung, and nasal epithelium associated Mm00465064_m1 
Pou2f3 POU domain, class 2, transcription factor 3 [Skn-1a, Oct-11] Mm00478284_m1 
Pramel1 preferentially expressed antigen in melanoma-like 1 Mm00473193_m1 
Prdx4 peroxiredoxin 4 Mm00450261_m1 
Prdx6 peroxiredoxin 6 Mm00725435_s1 
Prss33 protease, serine, 33 Mm00617657_m1 
Prss34 protease, serine, 34 Mm00617666_g1 
Ptpn4 protein tyrosine phosphatase, non-receptor type 4 Mm00480178_m1 
Pycard PYD and CARD domain containing Mm00445747_g1 
Rab23 RAB23, member RAS oncogene family Mm00436209_m1 
Rac2 RAS-related C3 botulinum substrate 2 Mm00485472_m1 
Ralgps1 Ral GEF with PH domain and SH3 binding motif 1 Mm00613690_m1 
Raly hnRNP-associated with lethal yellow Mm00499167_m1 
Rbpjl (Rbpsuhl) recombination signal binding protein for immunoglobulin kappa J 
region-like 
Mm00485631_m1 
Rem1 rad and gem related GTP binding protein 1 Mm00485674_m1 
Rnf24 ring finger protein 24 Mm00724270_m1 
Rnf32 ring finger protein 32 Mm00502428_m1 
Satb1 special AT-rich sequence binding protein 1 Mm00485916_m1 
Aimp1 (Scye1) ARS inducible multifunctional protein 1 Mm00433034_m1 
Serpina6 serine (or cysteine) peptidase inhibitor, clade A, member 6 Mm00432327_m1 
Serpinb9e serine (or cysteine) peptidase inhibitor, clade B, member 9e Mm00660208_m1 
Stab2 stabilin 2 Mm00454684_m1 
Tll2 tolloid-like 2 Mm00449432_m1 
Tlr5 toll-like receptor 5 Mm00546288_s1 
Tnfrsf26 tumor necrosis factor receptor superfamily, member 26 Mm00558700_m1 
Ubd ubiquitin D Mm00499179_m1 
Ube2d2 ubiquitin-conjugating enzyme E2D 2 Mm00785931_s1 
Scaper (Zfp291) S phase cyclin A-associated protein in the ER Mm00615854_m1 
 
 
 
 
 
 
Materials and Methods  32 
The n-fold expression levels were calculated by the ΔΔCt method. In addition to the “default”-
endogenous control gene (18S rRNA), we included another 3 endogenous control genes, namely 
Hmbs, Hprt and Ube2d2. Endogenous control genes should meet the following criteria: (i) they must 
not be regulated by any of the experimental parameters (treatment and genotype; Bustin, 2000), (ii) 
they should not vary more than 5-fold between the samples (Dheda et al., 2004) and (iii) the Ct values 
should be approximately in the same range like the Ct values of the target genes (Bustin, 2002). The 
Ct values for the 18SrRNA were rather low (between 9 and 11) compared to the Ct values of the target 
genes (between 20 and 35) and varied considerably (Figure 11). Hmbs even turned out to be regulated 
not only by LPS treatment, but also in a Tyk2-dependent fashion (see results). Since Ct value 
differences of Hprt and Ube2d2 did not exceed 2.3, i.e. 5-fold differences assuming 100% PCR 
efficiency, they met the criteria for endogenous control genes. Therefore the target-gene data were 
normalised to a mean of Hprt andUbe2d2 (for “R” statistics), or to Ube2d2 alone (for all other 
calculations). Usually, normalised data were calibrated to the untreated WT of the first experiment 
(1WT_0h = 1). 
 
 
 
Figure 11: Average Ct value differences for the endogenous controls. Ct values were calibrated 
to the first untreated WT sample (1WT_0h = 0), then averages and standard deviations from the 3 
Taqman® arrays were calculated.  
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Statistics for qPCR data 
For the statistical analysis of qPCR-data in general a linear model for one dependent variable was run 
in the program SPSS Statistics 17.0. In order to provide linearity of the data log-transformed data were 
used for the statistical analysis. Normalised ΔCt values which are per definition log(2) or the 
normalised log(10) transformed values derived from the standard curve method were submitted to 
statistical analysis. Mean values ± SE of independent experiments were calculated. To calculate the 
significances of the “genotype effect” the samples of the genotype in question were compared to their 
corresponding samples of the WT, e.g. Tyk2-/- at time point 6 hours compared to the WT at time point 
6 hours. Similarly, the significances of the “treatment effect” were calculated by comparing the treated 
to the untreated  samples of the different genotypes, e.g. WT at time point 6 hours compared to WT at 
0 h, and Tyk2-/- at time point 6h compared to Tyk2-/- at 0 hours. The independent experiments were 
considered as random factor in this statistical analysis.  
The results of the Taqman® Custom arrays were statistically “pre-screened” in order to filter for genes 
that differ significantly between WT and Tyk2-deficient cells. The qPCR results were analysed with 
the “R” statistical package (Many: The R-project. http://www.r-project.org/, February 2007). In 
general, results proved highly variable and thus unreliable for low expression levels. Therefore genes 
that had Ct values beyond 30 were excluded from further analysis. Out of 240 genes 106 genes were 
further analysed. The target-gene data were normalised to a mean of the 2 endogenous control genes 
Hprt and Ube2d2. These ΔCt values were standardised to the same means and variances for each 
genotype and treatment. Subsequently, a linear model with the effects of genotype, i.e., WT vs.  
Tyk2-/-, of time, i.e., before and after 1 hours and 6 hours LPS treatment, was computed for each gene 
separately. The distribution of standard deviations from this model was used to compute moderated t-
statistics (Smyth, 2004). This procedure ensured approximately t-distributed differences in gene 
expression values centered around a mean of about 0. Deviations from this mean were considered to 
be significant and highly significant if they exceeded the level of 2.14 and 2.96, i.e., the one-sided 
0.05- and 0.01-limit for the t-test, respectively. SPSS statistical analysis was performed for the genes 
found by the “R”-screen to be differentially regulated between WT and Tyk2-deficient PMs.  
 
Microarray analysis 
Two whole genome microarray studies were performed. In the first study, WT and Tyk2-/- PMs were 
treated with 100 ng/ml LPS for 6 hours in 3 independent experiments. For this experiment 
CodeLinkTM mouse whole genome microarrays were processed according to the manufacturer’s 
instructions (www.appliedmicroarrays.com; February 2007). Analysis is described in detail in the 
submitted manuscript Vogl et al., 2010. In the second study WT and Oct-6-/- FLMs were treated with 
50 µg/ml poly(I:C) for 8 hours in 3 independent experiments. This study was done with the ABI1700 
gene expression profiling system (Applied Biosystems).  
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For both studies, total RNA was isolated according to the TRiZOL protocol. The RNA for the 
microarray analysis fulfilled highest quality requirements. All RNAs showed high and uniform RNA 
integrity as assessed by capillary electrophoresis (Agilent Technologies; Figure 12) and absorption 
ratios 260 nm/280 nm of 2.1 as determined by photometry.  
 
 
Figure 12: Check of RNA quality by capillary electrophoresis. (A) LPS experiment in WT and 
Tyk2-/- PMs; (B) poly(I:C) experiment in WT and Oct-6 deficient FLMs. Total, TRiZOL isolated 
RNA was heated to 65°C for 3 minutes, loaded onto a mammalian total RNA Nano Chip (Agilent 
Technologies) and processed according to manufacturer’s instructions.  
 
ABI1700 whole genome arrays  
For the further analysis the RNA was handed over to an external institution, i.e. the Core Facility of 
Molecular Biology at the Centre for Medical Research of the Medical University of Graz, headed by 
Dr. Christian Gülly (Mouse whole genome arrays of the ABI1700 gene expression profiling system, 
Applied Biosystems).  
For normalisation and further calculation values less than 10 were set to 10. Each of the 12 chips was 
normalised to the 50th percentile, each gene was normalised to the median of all chips. A boxplot 
diagram of the normalised fluorescence values showed uniform distribution among the samples 
(Figure 13), therefore all 12 chips were included in the calculation.  
 
 
Figure 13: Normalised fluorescence data plotted for the 12 samples (s).  
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For statistical analysis (GeneSpring Expression Analysis 7.3.1 tool, Agilent Technologies) the data 
were filtered based on the signal to noise ratio. Samples were grouped according to the biological 
replicates (3x WT_0; 3x WT_poly(I:C); 3x Oct6_0; 3x Oct6_poly(I:C), and only genes that gave a 
signal to noise ratio above 2 in 3 out of 3 samples per group (i.e. all samples within at least 1 group), 
were included in the analyses. Under these conditions 12,220 out of 32,000 genes were further 
processed. The data were analysed for significant differences either between treated and untreated WT 
cells (treatment effect) or between treated Oct-6-deficient and treated WT cells (genotype effect after 
poly(I:C)). A 1-way ANOVA analysis was applied, using a parametric test, variances were not 
assumed equal (Welch t-test), and the cut off was set to p<0.05. Expression differences of at least 2-
fold were considered relevant. Not fully annotated probes, i.e. probes that did not correspond to an 
NCBI RefSeq, EST or RIKEN cDNA, were excluded.  
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RESULTS I   
 
Gene expression profiling in peritoneal macrophages in response to LPS treatment: role of Tyk2 
Tyk2 has a detrimental effect in lipopolysaccharide (LPS)-induced shock, as Tyk2-deficient, in 
contrast to wild type (WT) mice, are able to survive the endotoxic shock (Karaghiosoff et al., 2003). 
Peritoneal macrophages (PMs) from Tyk2-deficient mice showed reduced expression of the type I 
interferons (IFNs), IFNβ and IFNα4, as well as of the IFN regulatory factors (Irfs) Irf1 and Irf7 in 
response to LPS treatment. In order to more globally characterise the effect of Tyk2 deficiency on LPS 
responses of macrophages, whole mouse genome microarray analysis was performed comparing 
Tyk2-/- and WT PMs with or without LPS treatment. On the one hand, extensive bioinformatic 
analyses of differentially regulated genes/clusters were performed to identify correlations with (i) 5’ 
and 3’ regulatory elements (e.g. transcription factor binding sites and miRNA cognate sequences) and 
(ii) functional categories (Fuhrmann B. Diploma thesis; Vogl et al., 2010; accepted manuscript). On 
the other hand, and part of this thesis, gene expression patterns of selected genes were validated for the 
above study and analysed in more detail by RT-qPCR. We analysed gene expression patterns of 240 
genes (table 6 in the material and methods section) in a medium-throughput format using Taqman® 
Custom Arrays (Applied Biosystems). These genes included known IFN-regulated genes and genes 
for which we had indications from a previous microarray screen to be differentially regulated in the 
absence of Tyk2 after IFNβ treatment (C. Gausterer, unpublished).  
WT and Tyk2-deficient PMs were treated with LPS for 1 and 6 hours, or were left untreated. IFNβ 
expression levels were tested prior to microarray and Taqman® Array analysis in order to control for 
the stimulation and genotype effects, as reduced expression levels of IFNβ in the absence of Tyk2 had 
already been demonstrated. In WT PMs, the expression of IFNβ peaked at 1 hour and declined again 
after 6 hours of LPS treatment. As expected, the expression of IFNβ was significantly reduced in the 
absence of Tyk2 (see table 7 for statistical analysis). This was observed for basal expression levels, i.e. 
expression levels in untreated PMs, as well as for expression levels after LPS treatment (Figure 14).  
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Figure 14: Expression levels of IFNβ are reduced in the absence of Tyk2. WT and  
Tyk2-/- PMs were treated with LPS (100 ng/ml; 1 h, 6 h), or left untreated (0 h). Expression levels 
of IFNβ were determined by RT-qPCR using the standard curve method for calculation of the  
n-fold expression levels and normalising the data to Ube2d2. N-fold expression levels are depicted 
as relative mean values of 3 experiments ± SE in a log-scaled diagram.  
 
Of the 240 genes analysed, 22 genes were induced/reduced in response to LPS-treatment and showed 
altered expression levels in the absence of Tyk2. Most of them are known ISGs, namely Mx1, Irf1, 
Irf7, Gbp2, Ifit1, Ifit2, Ifi203, Oas1b, Stat1, Socs1, Socs2, Ccl5, Cxcl9, Tnfsf10, Ddx58 and Slfn8 
(Figure 15). Differences between the genotypes above 2-fold were considered as relevant (Figures 15-
17, table 7; genes with a significant, but only 1.5- to 2-fold differential expression are summarised in 
table 8). Most of the ISGs showed similar expression patterns (Figure 15), with expression levels in 
WT unchanged after 1 hour and increased after 6 hours of LPS treatment. In the absence of Tyk2, the 
expression levels were significantly reduced at all time points. Different patterns were only observed 
for Irf1, Socs1 and Socs2. The expression of Irf1 peaked after 1 hour of LPS treatment, and levels 
were again declining after 6 hours. However, significant reduction of Irf1 expression in the absence of 
Tyk2 was observed for all time points. In the case of Socs1, only the basal expression level was 
significantly reduced in the absence of Tyk2, whereas expression levels were comparable to those of 
WT cells after LPS treatment. In contrast, increased basal expression in the absence of Tyk2 was 
observed for Socs2. In addition, although Socs2 was induced upon LPS treatment in WT cells, its 
expression level after 6 hours was still significantly below that of Tyk2-deficient cells.  
 
Figure 15 – continued on the following pages  
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Figure 15 – continued on the following pages 
    
  
   
   
Results  39 
   
   
  
Figure 15: ISGs are differentially expressed in WT and Tyk2-deficient PMs after LPS 
treatment. WT and Tyk2-/- PMs were treated with LPS (100 ng/ml; 1 h, 6 h), or left untreated (0 
h). The n-fold expression levels were determined by RT-qPCR in the Taqman® array format, 
using the ΔΔCt method. The target gene data were normalised to Ube2d2 as endogenous control, 
the samples were calibrated to the untreated WT (i.e. WT_0h = 1). N-fold expression levels are 
depicted as relative mean values of 3 experiments ± SE in a log-scaled diagram (see table 7 for the 
statistical analysis). 
 
Six genes that so far have not been reported to be regulated by LPS treatment or to be dependent on 
Tyk2, namely Pou3f1, IL-17F, Fgr, Hmbs, Aif1 and Cd79a, were found to be expressed differentially 
between WT and Tyk2-deficient PMs (Figure 16). So far, they have not been reported to be induced in 
PMs, upon IFN-treatment, and/or to be dependent on Tyk2.  
The pattern of Oct-6 (Pou3f1) expression was comparable to that of most ISGs, with expression levels 
in WT cells being unchanged after 1 hour and increased after 6 hours of LPS treatment, and with 
largely reduced expression levels in the absence of Tyk2 at all time points (Figure 16A).  
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IL-17F was hardly detectable at basal levels (Ct > 35). The expression was increased already after 1 
hour and further increased after 6 hours of treatment. Significantly lower levels of IL-17F were found 
in the absence of Tyk2 after LPS treatment (Figure 16B). Since IL-17 has obtained quite some 
attention as being the signature cytokine of the Th17 subset of T-cells, expression of IL-17F and of the 
closely related, more prominent IL-17A was further analysed in separate qPCR assays. This improved 
the sensitivity so that also basal levels could be reliably detected. The results for IL-17F from the 
Taqman® Array could be confirmed and IL-17A showed similar expression patterns. In the absence of 
Tyk2, expression levels of IL-17F and IL-17A were significantly reduced at all time points (Figure 
17).  
Basal expression level of Aif1 and Cd79a (Figure 16C and 16D) were also reduced in the absence 
Tyk2. However, those genes were not significantly regulated in response to LPS in WT cells. Aif1 
expression was significantly downregulated upon LPS treatment in Tyk2-deficient cells.  
Expression levels of Fgr and Hmbs (Figure 16E and 16F) were downregulated after LPS treatment in a 
Tyk2-dependent manner. 
 
Figure 16 – continued on the following pages  
  
  
(A) (B) 
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Figure 16: Further genes showing altered expression patterns in the absence of Tyk2. WT 
and Tyk2-/- PMs were treated with LPS (100 ng/ml; 1 h, 6 h), or left untreated (0 h). N-fold 
expression levels were calculated as described above for Figure 15.  
 
  
 
Figure 17: Expression of IL-17F and IL-17A is induced in PMs after LPS treatment in a Tyk2-
dependent manner. In 3 independent experiments, WT and Tyk2-/- PMs were treated with LPS (100 
ng/ml; 1 h, 6 h), or left untreated (0 h). N-fold expression levels for IL-17F and IL-17A were 
determined as described above in Figure 14. 
 
Table 7: Significances of treatment and genotype effects for genes showing at least 2-fold 
differential expression between WT and Tyk2-/- PMs upon LPS treatment (ad Figures 14-17, 
table continued on the following page). 
 
gene 
treated versus untreated Tyk2-/- versus WT  
WT_1h WT_6h Tyk2-/-_1h Tyk2-/-_6h 0h 1h 6h 
IFNβ 1 ** ** ** ** ** ** ** 
Irf1 **  **  ** ** ** 
Irf7  *  ** ** ** ** 
Mx1  **  ** ** ** ** 
Gbp2  **  ** ** ** ** 
Ifit1  ** * ** ** ** ** 
Ifit2  **  ** ** ** ** 
(E) (F) 
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gene 
treated versus untreated Tyk2-/- versus WT  
WT_1h WT_6h Tyk2-/-_1h Tyk2-/-_6h 0h 1h 6h 
Ifi203  **  ** ** ** ** 
Oas1b  **  ** ** ** ** 
Stat1  *  * ** ** ** 
Socs1  ** ** ** **   
Socs2  *   *  * 
Ccl5  **  ** * * ** 
Cxcl9  **  ** ** ** ** 
Tnfsf10  ** * ** ** ** ** 
Ddx58  **  ** ** ** ** 
Slfn8  ** ** ** ** ** ** 
Pou3f1  **  * ** ** ** 
IL-17F ** **  *  ** ** 
IL-17F 1 ** ** ** ** ** ** ** 
IL-17A 1 ** ** ** ** ** ** ** 
Fgr ** ** ** **   ** 
Hmbs * **  **   ** 
Aif1   * ** ** ** ** 
Cd79a      *  
The normalised ΔCt values or the, normalised log(10) transformed (in case of the genes analysed 
separately) values were submitted to statistical analysis in SPSS.17.0 applying an univariate linear 
model. The results for the selected genes shown in figures 14-17 are summarised with ** 
indicating p<0.01, and * p<0.05, empty fields identify non-significant differences. ISGs are 
indicated by the shaded boxes. 
 
 
Table 8: Genes showing a significant 1.5- to 2-fold differential expression between WT and 
Tyk2-/- PMs after LPS treatment (table continued on the following page). 
 
 
gene 
treated versus untreated Tyk2-/- versus WT  
WT_1h WT_6h 0h 1h 6h 
As3mt  0.40 (**)   1.86 (**) 
Birc4   1.58 (**)   
Casp2 0.53 (**)    0.55 (**) 
Cias11 - 10.3 (**) 0.66 (*) -  
Ebi31 -   - 1.80 (**) 
Efnb2    1.96 (**)  
Eif2c1     1.62 (**) 
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gene 
treated versus untreated Tyk2-/- versus WT  
WT_1h WT_6h 0h 1h 6h 
Fmr1  2.25 (**)   0.51 (**) 
Gimap91 - 4.46 (**)  - 0.56 (**) 
Hipk2    1.72 (**)  
Icam21 -   - 0.54 (**) 
Lbp    0.52 (**)  
Mga  0.59 (**)   1.69 (**) 
Mitf1 -  1.60 (**) -  
Mmp13 1.53 (**) 10.6 (**)   0.52 (*) 
Nedd4  0.62 (**)  1.76 (**) 1.62 (**) 
Nr2f61 - 0.40 (**)  - 1.98 (**) 
Padi4  0.55 (**) 0.61 (*) 0.53 (**)  
Prdx61 -  1.67 (**) - 1.92 (**) 
Prkce  2.42 (**)   0.62 (**) 
Ptprm   1.55 (**) 1.66 (**)  
Rnf241 - 4.48 (**)  - 0.52 (**) 
WT and Tyk2-/- PMs were treated with LPS (100 ng/ml; 1h, 6h), or left untreated (0h). The n-fold 
expression levels were determined by RT-qPCR in the Taqman® array format, using the ΔΔCt 
method, normalising the gene-of-interest data to the mean of Ube2d2 and Hprt as endogenous 
controls. Genes giving Ct values of 30 and above were excluded from the analysis. The normalised 
ΔCt values were submitted to statistical analysis in “R” applying an univariate linear model (** 
indicate p<0.01, and * p<0.05, empty fields identify non-significant changes). For certain genes 
(1) 1 of the 3 replicates was missing for the 1 hour time point. That is why no statistical analysis 
could be performed for these genes for this time point (-).  
 
 
In summary, absence of Tyk2 had a profound effect on the expression of the ISGs analysed in this 
study. Following expression patterns in the absence of Tyk2 compared to WT were observed: (i) 
reduced expression at basal levels and after treatment with LPS (most ISGs), (ii) reduced basal 
expression, but similar to WT after LPS treatment (Socs1), (iii) enhanced expression at basal levels 
and after LPS treatment (Socs2). Six, novel Tyk2-dependent genes (displaying at least 2-fold 
differential expression as compared to WT) were identified and following patterns were found: (i) 
comparable to the expression pattern of most ISGs (Pou3f1, IL-17A, IL-17F), (ii) reduced expression 
at basal levels and after LPS treatment, whereby expression levels in WT were unchanged in response 
to treatment (Aif1, Cd79a), (iii) no difference at basal levels and enhanced expression after LPS 
treatment in comparison to WT (Fgr, Hmbs).  
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Oct-6 is an interferon stimulated gene (ISG) 
Oct-6 expression after IFNβ treatment in fibroblasts 
In a whole genome microarray study (C. Gausterer unpublished), octamer-binding-factor 6 (Oct-6; 
also known as Pou3f1, SCIP, Tst-1) was found to be induced in response to IFNβ treatment in murine 
embryonic fibroblast (MEF) cell lines. Expression of Oct-6 mRNA was reduced in the absence of 
Tyk2. Oct-6 belongs to the group of POU-domain containing transcription factors and is involved in 
terminal differentiation of myelinating Schwann cells and keratinocytes. Oct-6 has never been shown 
before to be expressed outside the neuroendocrine system and keratinocytes or to play a role in the 
context of type I IFN responses or in immunity in general.  
In the course of validation by reverse-transcription real-time quantitative PCR (RT-qPCR), microarray 
results were confirmed in MEF cell lines treated with IFNβ (Figure 18A). Corresponding experiments 
were performed in primary MEFs (pMEFs; Figure 18B). In both cell types, Oct-6 mRNA expression 
levels were induced about 40- to 60-fold after 6 hours of IFNβ treatment in wild type (WT) cells and 
only about 7- to 20-fold in the absence of Tyk2.  
 
 
Figure 18: Oct-6 mRNA expression is induced in MEF cell lines and pMEFs after IFNβ 
treatment and is partially dependent on Tyk2. Cells were treated with IFNβ (500 U/ml) for 6 
hours. (A) N-fold expression levels relative to untreated WT cells were determined by RT-qPCR 
in the Taqman® Custom Array format using the ΔΔCt method. Data were normalised to a mean of 
3 endogenous control genes (Hprt, Hmbs and Ube2d2). N-fold expression levels are depicted as 
mean values of 3 experiments ± standard deviation (SD; data in collaboration with C. Gausterer). 
(B) N-fold expression levels relative to untreated WT cells were determined by RT-qPCR using 
the standard curve method, using Ube2d2 for normalisation. Data are shown as mean values of 
technical duplicates ± SD for 1 representative out of 2 independent experiments.  
 
We were not able to reliably detect Oct-6 protein by western blot, since a strong background 
dominated over a weak specific signal. Therefore we analysed Oct-6 protein expression and DNA-
binding activity by bandshift assays using an oligonucleotide containing the octamer consensus motif.  
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Oct-6 DNA-binding was observed after treating WT pMEFs with IFNβ, whereas it was not detected in 
untreated cells (Figure 19). Since other members of the POU-family of proteins also bind to this 
oligonucleotide, identity of Oct-6 was confirmed by supershift assays with an Oct-6-specific antibody 
and by the absence of the signal in Oct-6-deficient cells (Figure 19A). A slower migrating protein or 
complex, which was present in all samples irrespective of treatment was identified as Oct-1, which is 
known to be ubiquitously expressed (Ryan and Rosenfeld, 1997). Another protein/complex, migrating 
between Oct-1 and Oct-6 (weak in Fig. 19A, better visible in Fig. 19B) was detected, but could not be 
assigned to a specific octamer-binding protein. Reduced IFNβ-induced Oct-6 expression in the 
absence of Tyk2 could also be confirmed by bandshift assays in MEF cell lines (data not shown) as 
well as in pMEFs (Figure 19B). 
 
  
 
Figure 19: Oct-6 protein is expressed in pMEFs in response to IFNβ treatment, and 
expression is partially dependent on Tyk2. (A) Oct-6+/+ and Oct-6-/- pMEFs were treated with 
IFNβ (1000 U/ml) for the indicated times. Whole cell extracts were analysed by bandshift assays 
with an octamer motif-containing probe (SS: supershifts with the respective antibodies (+AB); “?” 
unidentified octamer-binding complex). (B) WT and Tyk2-/- pMEFs were treated with IFNβ 
(1000 U/ml) for the indicated times. Bandshifts were performed as described in (A).   
 
 
Oct-6 induction after IFNβ treatment in macrophages  
Macrophages play a major role in immunity, and therefore the expression of Oct-6 in bone marrow-
derived macrophages (BMMs) upon IFNβ treatment was analysed. In general, Oct-6 DNA-binding 
activity was much higher induced in BMMs than in MEFs. Oct-6 protein was readily detected after 3 
hours and reached the maximum between 6 to 12 hours of IFNβ treatment (Figure 20A, B). As in 
MEFs, Oct-6 binding was not observed in untreated macrophages. Again, Oct-6 was identified by 
supershift with the respective antibody. Furthermore, Oct-6 overexpressed in a MEF cell line showed 
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the same migration in the bandshift gel (Figure 20A). Apart from Oct-6 and the ubiquitously expressed 
Oct-1, a third complex was observed in BMMs. This complex migrated between Oct-1 and Oct-6 and 
could be supershifted with an α-Oct-2 antibody, which is in line with previous publications 
demonstrating Oct-2 expression in various macrophage populations (Dunn et al., 1996 and references 
therein).  
 (A)                                                                  (B) 
     
Figure 20: Oct-6 is expressed in BMMs in response to IFNβ treatment. (A, B) WT BMMs 
were treated with IFNβ (1000 U/ml) for the indicated times. Whole cell extracts were analysed by 
bandshift assays with an oligonucleotide containing the octamer consensus motif. (A) +AB: 
supershifts with Oct-1, Oct-2 and Oct-6 specific antibodies; OX: transient overexpression of Oct-6 
in a MEF cell line.  
 
In order to elucidate the molecular requirements for the induction of Oct-6, BMMs deficient for 
components of the signalling pathway mediating IFNβ responses, namely Tyk2, Stat1, Ifnar1 and Irf1, 
were analysed by bandshift assays. In Tyk2-deficient macrophages, the binding of Oct-6 was clearly 
reduced (Figure 21), which is similar to the results obtained in pMEFs. In the absence of Stat1, Oct-6 
expression was nearly absent, and only very weakly detectable after 24 hours of IFNβ treatment. Irf1-
deficient cells were included in the analysis in order to test whether expression Oct-6 is directly 
dependent on Stat1, or whether Irf1 is required as an intermediate step, but absence of Irf1 did not 
affect Oct-6 induction. As expected, Oct-6 protein after IFNβ treatment was not detected in Ifnar1-
deficient BMMs, thus confirming that the effect on Oct-6 expression is mediated by IFNβ and not by 
any other component that might be present in the IFNβ solution. 
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Figure 21: Expression of Oct-6 in response to IFNβ is largely dependent on Jak/Stat 
signalling. WT, Stat1-/-, Tyk2-/-, Ifnar1-/- or Irf1-/- BMMs were treated with IFNβ (1000 U/ml) 
for the indicated times. Whole cell extracts were analysed by a bandshift assay with an 
oligonucleotide containing the octamer consensus motif (SS: Supershift of WT_8h lysates with an 
α-Oct-6 antibody). 
 
 
Oct-6 induction in response to other cytokines 
In order to test whether Oct-6 is also induced in response to other cytokines, BMMs were treated with 
IFNγ or IL-6, respectively. IFNγ also signals through Stat1, but in contrast to type I IFNs, which 
activate Stat1/Stat2 heterodimers, IFNγ activates mainly Stat1/Stat1 homodimers. IL-6 employs 
Jak/Stat signalling, but activates mainly Stat3. IFNγ induced detectable amounts of Oct-6 DNA-
binding activity, but slightly less and with a different kinetic than IFNβ (Figure 22). In contrast Oct-6 
protein was not detected in response to IL-6 treatment.  
 
 
Figure 22: Oct-6 expression is induced in response to IFNγ but not to IL-6. BMMs were 
treated with IFNβ (1000 U/ml), IFNγ (1000 U/ml), IL-6 (125 ng/ml), or were left untreated (Ctrl). 
Whole cell extracts were analysed by a bandshift assay with an oligonucleotide containing the 
octamer consensus motif.  
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Oct-6 induction in response to poly(I:C) and virus infection 
We next wanted to test, if Oct-6 is only induced in response to high levels of exogenous IFNβ, or also 
by endogenously produced type I IFNs. BMMs were infected with murine cytomegalovirus (MCMV) 
or stimulated with poly(I:C), a dsRNA analogon mimicking viral infection. Both stimuli strongly 
induced Oct-6 DNA-binding activity (Figure 23). The induction of Oct-6 in response to poly(I:C) 
treatment (Figure 23A) and MCMV infection (Figure 23B) was clearly dependent on type I IFN 
signalling, since Oct-6 protein could not be detected in Ifnar1-deficient BMMs. Consistent with the 
prominent role of IFNβ in viral infections, Oct-6 DNA-binding activity was hardly detectable after 
both stimuli in the absence of IFNβ. Thus, other type I IFNs can also induce Oct-6. In Tyk2-deficient 
BMMs reduced Oct-6 expression was observed upon both stimuli. In the absence of Stat1, poly(I:C) 
failed to induce detectable amounts of Oct-6 protein. In contrast, a very weak signal of Oct-6 DNA-
binding activity in Stat1-/- BMMs was detected after 24 hours of MCMV infection, which is similar to 
the results obtained after long IFNβ treatment. 
 
Figure 23 – continued on the following page 
(A) 
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Figure 23: Expression of Oct-6 in response to poly(I:C) and during MCMV infection is largely 
dependent on type I IFN and Jak/Stat signalling. WT, IFNβ-/-, Ifnar1-/-, Stat1-/-, or Tyk2-/- BMMs 
were (A) treated with poly(I:C) (50 µg/ml) or (B) infected with MCMV (MOI = 1) for the indicated 
times. Whole cell extracts were analysed by bandshift assays with an oligonucleotide containing the 
octamer consensus motif (SS: Supershift of WT_8h lysates with an α-Oct-6 antibody). 
 
 
Analysis of the Oct-6 promoter region 
Based on the fact that Oct-6 is induced in a largely Stat1-dependent manner after IFNβ treatment, the 
promoter region of Oct-6 was searched for potential IFN-stimulated response elements (ISREs) and 
IFNγ activated sites (GASs). Therefore a genomic region 10 kb upstream of the transcription start site 
was analysed. Assuming that only conserved sequence elements would be of interest regarding the 
functionality of a predicted transcription factor binding site (TFBS), the murine sequence was aligned  
to the corresponding human and rat sequences (Blast 2 sequences: 
http://blast.ncbi.nlm.nih.gov/bl2seq/wblast2.cgi; March 2008). Whereas the 2 rodent sequences 
showed a high degree of homology, only a few homologous regions were found for murine and human 
sequences. These sequence parts, i.e. -7691 to -8047, -4367 to -4500, -1598 to -3233, and -161 to -637 
(base counts correlate to the murine sequence), were submitted to TFBS analysis using “Patch” 
(http://www.gene-regulation.com/pub/programs.html; August 2008), a publicly available program 
scanning input sequences for potential TFBSs based on the Transfac database. A number of Stat1- and 
ISGF3-binding sites were predicted for each sequence part (data not shown). We decided to 
concentrate on the homolgous sequence part nearest to the transcription start site (-161 to -637) of  
Oct-6, based on a report showing that the regions 500 bp upstream of the transcription start site of 
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IFN-inducible genes are enriched in predicted binding sites for Stat1, ISGF3, Irf1 and NFκB (Ananko 
et al., 2007). One GAS (-477 to -468) and one ISRE (-412 to -409) were predicted. Another GAS  
(-402 to -392) located in close proximity to the predicted ISRE was found by checking the sequences 
next to the predicted sites manually. The GAS elements (Figure 24) show only one mismatch each 
compared to the consensus sequence (TTC(N)2-4GAA; Decker et al., 1997). The predicted ISRE (-412 
to -409) seems rather imperfect when compared to the published consensus motif 
(GATTTC(N)2TTTCNY; Decker et al., 1997), but is identical in comparison to the Transfac annotated 
ISGF3 motif (GGAAA; accession number in Transfac database: HS$IFI616_01).  
 
 
 
Figure 24: Two GAS and one ISRE elements are predicted in the region 500 bp upstream of 
the Oct-6 transcription start site. The homologous sequence part containing the predicted Stat1 
binding sites, i.e. 2 GAS (black bold letters) and one ISRE (grey bold letters), is shown (base 
counts correlate to the murine sequence). The primer set for the short Oct-6-ChIP-PCR (Oct-6_S;  
-481 to -387; results in Figure 25A) is indicated by arrows. For the long Oct-6-ChIP-PCR  
(Oct-6_L; -481 to -243; results in Figure 25B), the same forward primer as for the short PCR was 
used. The corresponding reverse primer is located 150 bases downstream of the reverse primer of 
the short PCR and is not shown in this figure.  
 
 
Stat1 binding to the Oct-6 promoter 
In order to test Stat1 binding to the potential GAS and ISRE sites in the Oct-6 promoter a chromatin 
immunoprecipitation (ChIP) approach was used. Two PCRs covering the predicted sites were 
designed to analyse whether Stat1 binds to this region after IFN treatment (Figure 25). As a control, 
Stat1 binding to the GAS within the Irf1 promoter (Sadzak et al., 2008) was included in the analysis.  
Both PCRs for the Oct-6 promoter (Figure 25A, B) clearly show that IFNβ as well as IFNγ treatment 
induce Stat1 binding to the respective region. The signals for the untreated samples correlate to 
background (unspecific AB controls). As expected, Stat1 binding to the Irf1 promoter could be 
demonstrated in response to IFNβ and IFNγ treatment (Figure 25C).  
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Figure 25: Upon IFN treatment Stat1 binds to a region in the Oct-6 promoter containing potential 
GAS and/or ISRE motifs. BMMs were treated with IFNβ (500 U/ml) or IFNγ (200 U/ml) for the 
indicated times, or were left untreated (Ctrl). ChIP assays for Stat1 (α-Stat1 AB) were performed, 
followed by PCRs: (A) Oct-6_S, (B) Oct-6_L (Figure 24), (C) PCR for a region in the Irf1 promoter 
known to contain GAS elements. Rabbit serum was used as an unspecific antibody control (Ctrl AB), 
input DNA was amplified to control for DNA amount/loading prior to the immunoprecipitation step.  
 
 
Subcellular localisation of Oct-6 protein 
So far, no postranslational modifications required for full transcriptional activity of Oct-6 have been 
described. The transcriptional activity of Oct-6 seems to be regulated by its expression and possibly by 
its subcellular localisation (Baranek et al., 2005). In order to investigate if IFN treatment results in 
nuclear accumulation of Oct-6, an indirect immunofluorescence approach was followed. Since Oct-6 
is stronger induced in macrophages than in MEFs and Oct-6-deficient mice die perinatally, fetal liver-
derived macrophages (FLMs) were used in these experiments. Similar induction of Oct-6 in FLMs as 
compared to BMMs was confirmed by bandshift assays (Figure App. 2). FLMs were treated with 
IFNβ or poly(I:C) and subcellular localisation was analysed. As shown in Figure 26, Oct-6 is 
prominently detected in the nucleus in response to both stimuli. No Oct-6 staining was observed in 
untreated (Figure 26) and in Oct-6-deficient cells (data not shown).  
 
 
Figure 26: Oct-6 is located in the nucleus after IFNβ or poly(I:C) treatment. FLMs were grown on 
glass slides, treated with IFNβ (1000 U/ml) or poly(I:C) (50 µg/ml) for 8 hours, or were left untreated 
(Ctrl). Oct-6 was detected by immunofluorescence with an α-Oct-6 primary antibody and a 
fluorescently labeled secondary antibody. 
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Oct-6 expression in the murine Schwann cell line SW10 
Expression and function of Oct-6 have been mainly described in the context of Schwann cell 
development. Therefore the murine Schwann cell line SW10 was analysed for the expression of Oct-6 
in response to IFNβ treatment. This cell line was immortalised with a temperature sensitive variant of 
the SV40 large T-antigen (Hai et al., 2002). Cells were kept at 33°C (permissive temperature), 37°C 
and 39°C (non-permissive temperatures), and stimulated with IFNβ. Oct-6 mRNA was clearly induced 
independent of the culture conditions (Figure 27A). Interestingly, basal expression levels of Oct-6 
mRNA were enhanced with increasing temperature, i.e. more than 10-fold at 39°C as compared to 
33°C. Consistently, Oct-6 DNA-binding activity was detectable in response to IFNβ treatment in a 
temperature dependent manner. However, Oct-6 DNA-binding activity was rather weak (Figure 27B) 
as compared to MEFs and macrophages.  
 
  
 
 
 
Figure 27: Oct-6 is expressed in the murine Schwann cell line SW10 after IFNβ treatment. Cells 
were kept at the 3 different temperatures for three days (33°C, 37°C and 39°C) and were treated with 
IFNβ (1000 U/ml, for the indicated times) or left untreated (Ctrl). (A) Oct-6 mRNA expression was 
analysed by RT-qPCR applying the standard curve method with Ube2d2 as endogenous control (mean 
values of technical duplicates ± SD from 1 representative out of 2 independent experiments are shown). 
(B) Whole cell extracts were analysed by a bandshift assay with an octamer motif-containing 
oligonucleotide, 1 representative out of 2 experiments is shown.  
 
(A) 
(B) 
Results  53 
In summary, we found that Oct-6 was expressed in fibroblasts, macrophages and the murine Schwann 
cell line SW10 after stimulation with IFNβ. More detailed analyses in macrophages showed that IFNγ 
also induces Oct-6 expression. Furthermore, Oct-6 was induced in response to poly(I:C) treatment and 
during viral infections, in both cases in a strictly type I IFN-dependent manner. The expression of Oct-
6 was largely dependent on Stat1, and we could demonstrate Stat1 binding to a region in the Oct-6 
promoter in response to IFNβ or IFNγ treatment. Moreover, we showed that Oct-6 localised to the 
nucleus after IFNβ or poly(I:C) treatment.  
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The role of Oct-6 in innate immunity 
In order to analyse the biological function of Oct-6 in the setting of innate immunity two 
complementary approaches were followed. On the one hand, gain-of-function experiments were 
performed by overexpressing Oct-6 in primary fibroblasts (pMEFs). On the other hand, pMEFs and 
fetal-liver derived macrophages (FLMs) deficient for Oct-6 were analysed in loss-of-function 
experiments. Since Oct-6 is a transcription factor, we mainly focussed on the analysis of candidate 
target gene expression using RT-qPCR. Egr2 and Pmp22 were analysed, because both genes are 
known to be regulated by Oct-6 in the course of Schwann cell development (Ghislain et al., 2002; Ryu 
et al., 2007). Furthermore, expression levels of IFNαs (all subtypes collectively, panIFNα), IFNβ and 
iNOS, all of which contain functional octamer motifs in their promoters (Mesplède et al., 2005; 
Haggarty et al., 1991; Kleinert et al., 2004), were analysed. Moreover, a microarray experiment was 
performed in search for the role of Oct-6 in regulation of the transcriptional responses to poly(I:C) in 
macrophages. 
 
Candidate target gene expression upon Oct-6 overexpression 
For overexpression of Oct-6 the respective coding sequence was cloned into an expression plasmid 
under the control of the constitutively active EF1α-promoter (pEFZeo; Oct6_sense1). In order to 
control for unspecific effects, the antisense sequence of Oct-6 (Oct6_anti) was also cloned. 
Additionally, a CMV-promoter driven Oct-6 expression plasmid was used (Oct6_sense2). Oct-1 was 
cloned into pEFZeo (Oct1_sense), as a positive control, as effects of Oct-1 on IFNα expression have 
already been described (Mesplède et al., 2005). To control for transfection efficiency and for 
unspecific transfection effects an enhanced-GFP expression plasmid (GFP) and the empty pEFZeo 
plasmid were included in these experiments. Primary MEFs were transiently transfected with the 
different plasmids and gene expression of candidate target genes was analysed 24, 36 and 48 hours 
after transfection.  
As expected, transient induction of IFNβ was observed in response to transfection of the control 
plasmids, i.e. the empty vector, the GFP-plasmid and the Oct-6 antisense plasmid (Figure 28A). 
However, expression levels of IFNβ and also of panIFNα (Figure 28B) were significantly higher when 
Oct-6 (or Oct-1) was overexpressed. Expression levels of IFNβ 48 hours after transfection were 
approximately 10- to 100-fold higher upon overexpression of Oct-6 than after transfection of the 
control plasmids (Figure 28A). Thus, we conclude that in addition to the PRR-mediated induction of 
type I IFNs, which is also observed with the control plasmids, an Oct-6- (also Oct-1-) specific effect 
leads to the continued high-level expression of type I IFNs.  
No differences between transfection of Oct-6/Oct-1 overexpression and control plasmids were 
observed for Egr2 and Pmp22 expression 36 and 48 hours after transfection (Figures 28C, D). Egr2 
expression levels were slightly (about 2-fold) reduced 24 hours after transfection. However, the effects 
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of transfection observed were independent of Oct-6. Expression levels of iNOS could not be 
determined, because the respective mRNA could not be reliably detected in pMEFs (all Ct>33).  
 
Figure 28 – continued on the following page. 
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Figure 28: Expression levels of IFNβ and panIFNα but not of Egr2 and Pmp22 are strongly 
enhanced by the overexpression of Oct-6. WT pMEFs were transfected with empty vector 
(pEFZeo), enhanced-GFP expression vector (GFP), 2 different plasmids for Oct-6 expression 
(Oct6_sense1/2), a plasmid containing Oct-6 cDNA in antisense direction (Oct6_anti), and a 
plasmid for Oct-1 expression (Oct1_sense). As a control untransfected cells (Ctrl) were analysed. 
mRNA levels of (A) IFNβ, (B) panIFNα, (C) Egr2 and (D) Pmp22 were determined by RT-qPCR 
at 24, 36, and 48 h after transfection. N-fold expression values were calculated relative to the 
untransfected control (Ctrl_24h=1) using the standard curve method with Ube2d2 as endogenous 
control. PanIFNα could not be detected in untransfected cells, therefore the n-fold expression 
levels were just normalised to the endogenous control, thus reflecting panIFNα mRNA levels in 
relation to the endogenous control gene (mean values ± SD from 3 independent experiments). 
 
Candidate target gene expression in Oct-6-deficient fibroblasts after DNA transfection 
In order to analyse the impact of endogenous Oct-6 on candidate target gene expression, WT and  
Oct-6-deficient pMEFs were transfected with the GFP-plasmid and gene expression was analysed 3, 8 
and 24 hours after transfection. As expected, expression of IFNβ and panIFNα were strongly induced 
in response to GFP plasmid transfection (Figure 29A, B). This induction was transient and peaked at 3 
hours after transfection. In contrast to the data shown before (Figure 28A, B), type I IFN expression 
was almost back to basal levels at 24 hours after transfection in these experiments, which is most 
likely due to the different genetic background of the cells. Whereas for the overexpression 
experiments WT cells with C57BL/6 background were used, the WT (Oct-6+/+) and Oct-6-deficient 
cells here are of mixed genetic background. However, absence of Oct-6 did not have any impact on 
IFNα/β expression.  
In WT pMEFs, Egr2 mRNA expression was about 2-fold increased at 3 hours and about 2-fold 
decreased at 24 hours post transfection (Figure 26C and Figure 29C). Expression levels of Pmp22 
mRNA were transiently reduced at 8 hours (Figure 29D) and back to the untreated level at 24 hours 
post transfection (Figure 29D and Figure 28D). In both cases, the observed effects were independent 
of Oct-6. Similarly, no effect of Oct-6 on the expression of IFNβ, panIFNα, Egr2 and Pmp22 could be 
observed in preliminary experiments using poly(I:C) instead of DNA transfection and in response to 
MCMV infection (Figures App. 3-5).  
(D) 
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Figure 29: Absence of Oct-6 does not influence the expression patterns of panIFNα, IFNβ, 
Egr2 and Pmp22 upon GFP transfection in pMEFs. WT and Oct-6-deficient (Oct-6-/-) pMEFs 
were transfected with enhanced-GFP expression vector (GFP) or were left untransfected (Ctrl). 
mRNA levels of (A) panIFNα, (B) IFNβ, (C) Egr2 and (D) Pmp22 were determined by RT-qPCR 
at 3, 8, and 24 hours after transfection. N-fold expression values were calculated relative to 
untransfected WT cells (WT_Ctrl=1) using the standard curve method with Ube2d2 as endogenous 
control. PanIFNα was not detectable at basal levels, n-fold expression levels were calculated as 
described in Figure 25 (mean values ± SD from 3 independent experiments). 
 
 
Candidate target gene expression in Oct-6-deficient macrophages after poly(I:C) treatment 
Since a stronger induction of Oct-6 DNA-binding activity in response to type I IFN (Figure 20) and 
poly(I:C) (Figure 23A) treatment has been observed, loss-of-function experiments were also 
performed in macrophages. WT and Oct-6-deficient FLMs were treated with poly(I:C) for 8 hours and 
candidate target gene expression was analysed. IFNβ, panIFNα and iNOS were strongly induced in 
response to poly(I:C) treatment in FLMs (Figure 30A-C). Egr2 and Pmp22 expression was reduced 
about 2-fold after poly(I:C) treatment (Figure 30D, E). However, none of the observed effects was 
dependent on the presence of Oct-6. In addition, preliminary experiments revealed no role for Oct-6 
for the expression of these 5 genes in FLMs after longer poly(I:C) treatment, with or without IFNβ or 
IFNγ pretreatment (Figures App. 6-12).  
(A) (B) 
(C) (D) 
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Figure 30: Absence of Oct-6 does not influence the expression of IFNβ, panIFNα, iNOS, 
Egr2 and Pmp22 in FLMs after poly(I:C) treatment. WT and Oct-6-deficient (Oct-6-/-) FLMs 
were treated with poly(I:C) (50 µg/ml) for 8 hours or were left untreated (Ctrl). Gene expression of 
(A) IFNβ, (B) panIFNα, (C) iNOS, (D) Egr2 and (E) Pmp22 was determined by RT-qPCR. N-fold 
expression values were calculated relative to the untreated WT cells (WT_Ctrl = 1) using the 
standard curve method with Ube2d2 as endogenous control. Basal levels for panIFNα and iNOS 
could not be detected, n-fold expression levels were calculated as described in Figure 25 (mean 
values ± SD from 3 experiments). 
 
 
MCMV replication in Oct-6-deficient macrophages 
MCMV infection strongly induced Oct-6 expression and DNA-binding activity in macrophages 
(Figure 23B). In order to investigate the role of Oct-6 also in a more complex cellular readout than the 
analysis of candidate target gene expression, MCMV replication was analysed comparing WT and 
Oct-6-deficient FLMs. As already reported for BMMs (Strobl et al., 2005), FLMs were quite resistant 
to MCMV infection with an increase in viral titres of about 2 logs after 6 days of infection at an MOI 
of 1 (Figure 31). No differences in viral titres were observed between WT and Oct-6-deficient FLMs. 
Similarly, no difference was found using an MOI of 0.1 (Figure App. 15). 
(A) (B) (C) 
(D) (E) 
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Figure 31: The absence of Oct-6 does not influence MCMV replication rates in FLMs. WT 
and Oct-6-deficient FLMs were infected with MCMV at an MOI of 1. Supernatants were taken at 
1 hour (0 d), 1, 3 and 6 days (d) after infection. Virus titres were determined by plaque forming 
assays with Stat1-deficient MEFs. Mean values ± SD of 4 independent experiments are shown.  
 
 
In summary, absence of endogenous Oct-6 had no influence on panIFNα and IFNβ expression in 
any of the experiments described above, although a striking effect of Oct-6 overexpression on the 
expression of type I IFNs had been observed. Expression levels of Egr2 and Pmp22, two genes 
regulated by Oct-6 during Schwann cell development, were not influenced by either 
overexpression or absence of Oct-6. In addition, endogenous Oct-6 had no detectable impact on 
MCMV replication.  
 
 
Microarray analysis: WT versus Oct-6-deficient macrophages after poly(I:C) treatment 
In search for potential target genes of Oct-6 a whole genome microarray experiment was performed. In 
3 independent experiments WT and Oct-6-deficient FLMs were treated with poly(I:C) for 8 hours. An 
external institution (Dr. Christian Gülly, Core Facility of Molecular Biology, Centre for Medical 
Research, Medical University of Graz) was appointed to run and analyse the microarrays (Applied 
Biosystems, ABI 1700 mouse whole genome microarrays). Poly(I:C) treatment of WT FLMs had a 
dramatic impact on the transcriptome with approximately 3500 genes (out of 12220 genes included in 
the analysis) significantly regulated (p<0.05; minimal fold change upon treatment of 2; Figure 32). 
About one third of the 4000 genes were upregulated and the rest of the genes was downregulated.  
According to the Gene Ontology (GO) annotation (GeneSpring Expression Analysis 7.3.1 tool, 
Agilent Technologies), genes involved in immune responses and cell death were significantly enriched 
in the set of genes up-regulated in response to poly(I:C) treatment (table App. 1). In the set of genes 
down-regulated in response to poly(I:C) treatment, genes involved in metabolism and cell cycle 
progression were significantly enriched (table App. 2).  
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Figure 32: Poly(I:C) treatment has a strong impact on the macrophage transcriptome. 
Expression patterns of WT and Oct-6-deficient FLMs treated with poly(I:C) (50 µg/ml for 8 hours; 
3 independent experiments) are illustrated by heatmaps. Significant differences in gene expression 
(minimum 2-fold, p<0.05; analysed with GeneSpring Expression Analysis tool, 7.3.1, Applied 
Biosystems) are shown. 
 
A subset of genes (201 genes; tables App. 3, 4) was found to be more than 2-fold differentially 
expressed between WT and Oct-6-deficient macrophages after poly(I:C) treatment (p<0.05). About 
two thirds of the differentially expressed genes were reduced (125 genes; table App. 3), whereas 
enhanced gene expression was observed for 86 genes (table App. 4) in Oct-6-deficient FLMs as 
compared to WT cells. Oct-6 was still detectable in Oct-6-deficient cells, but expression levels were 
about 5-fold reduced (table 9) as compared to WT cells. Oct-6 deficiency results from a targeted 
disruption of the DNA-binding domain by insertion of a lacZ/Neo-cassette (Jaegle et al., 1996). A 
bicistronic mRNA is produced from the targeted locus, which was obviously detected by the Oct-6 
microarray probe.  
Functional annotation and clustering of the differentially regulated genes was performed using the 
Gene Functional Classification tool of the database for annotation, visualization and integrated 
discovery (DAVID; http://david.abcc.ncifcrf.gov/; Dennis et al., 2003; Huang et al., 2008). Of the 201 
genes about half (n=97) could be grouped into classes/pathways (table 9). The largest group was 
“Regulation of transcription” containing 16 genes, most of them down-regulated in the absence of 
Oct-6, such as Gtf2f2, Egr3, Btg1 and a number of zinc finger proteins. A related category “RNA 
splicing” contained 3 genes, Sfrs14, Lsm10 and Sf3a1, all of which showed reduced expression in the 
absence of Oct-6. Another category “Ubiquitin cycle” contained 6 genes, half of which were up-, half 
downregulated. However, analyses for pathway enrichment could not be performed, because the 
number of differentially regulated genes was too low as opposed to the vast amount of potential GO-
categories and did not yield any significant result. However, we found that Oct-6 exerts positive and 
Genes up-regulated  
after poly(I:C) 
n=1141 
 
 
 
 
Genes  down-regulated  
after poly(I:C) 
n=2427 
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negative regulatory functions on the transcriptional responses to poly(I:C), and it is involved in 
regulation of a number of different pathways. 
 
Table 9: Genes differentially regulated between WT and Oct-6-deficient FLMs after poly(I:C) 
treatment grouped according to GO annotation (table continued on the following pages). 
Probe ID FC p-value Gene Symbol RefSeq Description 
Regulation of transcription (GO-BP GO:0045449) 
466313 0.3 0.0173 Pou3f1 NM_011141.1 POU domain, class 3, transcription factor 1 
876633 0.3 0.0075 Ctnnd2 NM_008729.1 catenin (cadherin associated protein), delta 2 
834086 0.3 0.0044 Rcor3 NM_144814.2 REST corepressor 3 
515044 0.3 0.0101 Zfp691 NM_183140.1 zinc finger protein 691 
452181 0.3 0.0433 Zmiz1 NM_175264.2 zinc finger, MIZ-type containing 1 
553608 0.3 0.0014 Gtf2f2 NM_026816.3 general transcription factor IIF, polypeptide 2  
315360 0.3 0.0201 Zfp775 NM_173429.1 zinc finger protein 775 
784635 0.3 0.0077 9630041N07Rik NM_173387.1 RIKEN cDNA 9630041N07 gene 
339824 0.4 0.0122 Egr3 NM_018781.1 early growth response 3 
360325 0.4 0.0182 Foxk2 NM_001080932.2 forkhead box K2 
675560 0.4 0.0480 Zfp414 NM_026712.1 zinc finger protein 414 
883636 0.5 0.0356 Btg1 NM_007569.2 B-cell translocation gene 1, anti-proliferative 
388184 2.3 0.0176 8430426H19Rik NM_178875.4 RIKEN cDNA 8430426H19 gene 
674148 2.9 0.0017 Snx13 NM_001014973.2 sorting nexin 13 
576988 3.2 0.0208 2810021J22Rik NM_172403.2 RIKEN cDNA 2810021J22 gene 
906799 3.3 0.0034 E4f1 NM_007893.1 E4F transcription factor 1 
RNA splicing (GO-BP GO:0008380) 
466728 0.4 0.0481 Sfrs14 NM_172755.2 splicing factor, arginine/serine-rich 14 
782547 0.4 0.00236 Lsm10 NM_138721.1 U7 snRNP-specific Sm-like protein LSM10 
685184 0.5 0.00992 Sf3a1 NM_026175.5 splicing factor 3a, subunit 1 
Telomere organization and biogenesis (GO-BP GO:0032200) 
687306 0.3 0.00876 Terc NR_001579.1 telomerase RNA component 
705683 3.1 0.00343 Pot1b NM_028370.1 protection of telomeres 1B 
Regulation of Ras protein signal transduction (GO-BP GO:0046578) 
509621 0.4 0.0077 Arhgef11 NM_001003912.1 Rho guanine nucleotide exchange factor (GEF) 11
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Probe ID FC p-value Gene Symbol RefSeq Description 
600711 0.4 0.0249 Tbc1d16 NM_172443.2 TBC1 domain family, member 16 
603800 0.4 0.0456 Arhgef16 NM_001112744.1 Rho guanine nucleotide exchange factor (GEF) 16
832842 2.6 0.0206 Arhgef4 NM_183019.2 Rho guanine nucleotide exchange factor 4  
G-protein coupled receptor protein signaling pathway (GO-BP GO:0007186) 
461332 0.3 0.016 Olfr1410 NM_146491.1 olfactory receptor 1410 
498376 0.3 0.0336 Olfr982 NM_146854.1 olfactory receptor 982 
538641 0.3 0.0485 Oprd1 NM_013622.2 opioid receptor, delta 1 
900911 0.4 0.015 Olfr1425|Olfr1426NM_001011853.1 olfactory receptor 1425|olfactory receptor 1426 
371452 0.4 0.0219 Olfr167 NM_146935.1 olfactory receptor 167 
405218 0.4 0.0321 Cysltr2 NM_133720.1 cysteinyl leukotriene receptor 2 
302319 0.4 0.0143 Pcsk1n NM_013892.2 proprotein convertase subtilisin/kexin type 1 inhibitor 
576856 0.4 0.0138 Olfr1013 NM_146762.1 olfactory receptor 1013 
498112 2.3 0.0316 Cacnb4 NM_146123.1 calcium channel, voltage-dependent, beta 4 subunit 
895890 2.5 0.00311 Olfr598|Olfr597 NM_001011845.1 olfactory receptor 598|olfactory receptor 597 
496110 2.5 0.0169 Olfr310 NM_001011520.1 olfactory receptor 310 
388075 2.8 0.0427 Adra2a NM_007417.4 adrenergic receptor. alpha 2a 
Monovalent inorganic cation transport (GO-BP GO:0015672) 
455948 0.5 0.0299 Kcnj2 NM_008425.2 potassium inwardly-rectifying channel, subfamily J, member 2 
620798 0.5 0.0405 Catsper3 NM_029772.1 cation channel, sperm associated 3 
554608 0.5 0.0392 Slc8a1 NM_011406.2 solute carrier family 8 (sodium/calcium exchanger), member 1 
Vitamin B6 biosynthetic process (GO-BP GO:0042819) 
480631 0.5 0.0473 Pdxk NM_172134.1 pyridoxal (pyridoxine, vitamin B6) kinase 
533138 2.9 0.0472 Pnpo NM_134021.1 pyridoxine 5'-phosphate oxidase 
Ubiquitin cycle (GO-BP GO:0006512) 
628730 0.3 0.0383 Rnf41 NM_026259.2 ring finger protein 41 
643747 0.4 0.0294 Klhl12 NM_153128.1 kelch-like 12 (Drosophila) 
665024 0.5 0.0434 Znrf4 NM_011483.1 zinc and ring finger 4 
381530 2.5 0.0337 Senp5 NM_177103.4 SUMO/sentrin specific peptidase 5 
363922 2.9 0.0324 Yod1 NM_178691.2 YOD1 OTU deubiquitinating enzyme 1 homologue (S. cerevisiae)NA 9930028C20 gene 
308725 4.2 0.0152 Senp8 NM_027838.2 SUMO/sentrin specific peptidase 8 
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Protein palmitoylation (GO-BP GO:0018345) 
617536 0.2 0.0124 Zdhhc3 NM_026917.4 zinc finger, DHHC domain containing 3 
437482 0.4 0.0111 Zdhhc17 NM_172554.1 zinc finger, DHHC domain containing 17 
Protein kinase activity (GO-MF GO:0004672) 
922907 0.3 0.0156 Map3k12 NM_009582.2 mitogen activated protein kinase kinase kinase 12
467664 0.3 0.0256 Epha10 NM_177671.2 Eph receptor A10 
851957 0.4 0.00638 Stk40 NM_028800.2 serine/threonine kinase 40 
627826 2.3 0.0465 Prkci NM_008857.2 protein kinase C, iota 
530372 2.4 0.0141 Epha4 NM_007936.2 Eph receptor A4 
837461 2.4 0.0336 Wnk1 NM_198703.1 WNK lysine deficient protein kinase 1 
357720 2.9 0.0036 Phka1 NM_008832.2 phosphorylase kinase alpha 1 isoform 1 
926998 3.3 0.00111 Rab38 NM_028238.5 Rab38, member of RAS oncogene family 
464717 4.6 0.00766 Dyrk1b NM_010092.1 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1b 
N-methyltransferase activity (GO-MF GO:000817) 
642032 2.9 0.0374 1190005F20Rik NM_026876.3 RIKEN cDNA 1190005F20 gene 
375317 3.3 0.0017 Setmar NM_178391.2 SET domain and mariner transposase fusion gene 
Zinc ion binding (GO-MF GO:0008270) 
632096 0.4 0.0318 4933422H20Rik NM_001033775.3 RIKEN cDNA 4933422H20 gene 
789662 0.4 0.0232 2610507B11Rik NM_001002004.1 RIKEN cDNA 2610507B11 gene 
871506 0.4 0.0258 Gne NM_015828.2 glucosamine 
325670 0.4 0.0463 Zfp11 NM_172462.1 zinc finger protein 11 
594289 2.1 0.0157 AU017455 NM_001033215.2 EST AU017455 
375461 2.4 0.00775 2010315B03Rik XM_001472446.1 RIKEN cDNA 2010315B03 gene 
887858 2.4 0.00669 Ppp1r10 NM_175934.2 protein phosphatase 1, regulatory subunit 10 
721573 2.8 0.00086 Mpi NM_025837.2 mannose phosphate isomerase 
ATPase activity (GO-MF GO:0016887) 
409901 0.5 0.0299 Vps4b NM_009190.2 vacuolar protein sorting 4b (yeast) 
807992 2.2 0.0411 Ddx27 NM_153065.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 
556097 2.4 0.0238 Abcd4 NM_008992.1 ATP-binding cassette, sub-family D (ALD), member 4 
Mitochondrion (GO-CC GO:0005739) 
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331903 0.4 0.0179 4931431F19Rik XM_133663.5 RIKEN cDNA 4931431F19 gene 
606179 0.4 0.00383 Pars2 NM_172272.1 prolyl-tRNA synthetase (mitochondrial)(putative)
892845 0.4 0.0327 Slc25a36 NM_138756.2 solute carrier family 25, member 36 
663810 0.4 0.019 Papd1 NM_026157.1 PAP associated domain containing 1 
770438 0.5 0.0418 Slc25a23 NM_025877.2 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 
744134 2.1 0.017 Timm9 NM_001024853.1 translocase of inner mitochondrial membrane 9 homolog (yeast) 
626456 2.4 0.00167 Grpel1 NM_024478.2 GrpE-like 1, mitochondrial 
Endoplasmatic reticulum (GO-CC GO:0005783)  
460096 0.2 0.0295 Caml NM_007596.2 calcium modulating ligand 
731197 0.3 0.00332 Rcn3 NM_026555.1 reticulocalbin 3, EF-hand calcium binding domain
670264 0.4 0.0403 Arsg NM_028710.2 arylsulfatase G 
720766 2.4 0.0126 Duoxa2 NM_025777.1 dual oxidase maturation factor 2 
Integral to membrane (GO-CC GO:0016021) 
608851 0.2 0.0386 Tspan31 NM_025982.4 tetraspanin 31 
360339 0.3 0.0464 Klra2 NM_008462.4 killer cell lectin-like receptor, subfamily A. member 2 
852764 0.4 0.0497 Flrt3 NM_178382.2 fibronectin leucine rich transmembrane protein 3 
925399 0.4 0.0239 Lect1 NM_010701.1 leukocyte cell derived chemotaxin 1 
412730 0.4 0.0323 Tmem86b NM_023440.2 transmembrane protein 86B 
552370 0.4 0.0162 Tmem183a NM_020588.2 transmembrane protein 183A 
365471 0.4 0.00268 Col13a1 NM_007731.1 procollagen, type XIII, alpha 1 
564703 0.5 0.00496 Cmtm7 NM_133978.1 CKLF-like MARVEL transmembrane domain containing 7 
828936 0.5 0.0143 E030010A14Rik NM_183160.1 RIKEN cDNA E030010A14 gene 
754664 2.4 0.0201 Tnfrsf17 NM_011608.1 tumor necrosis factor receptor superfamily, member 17 
513587 2.5 0.0386 Cd276 NM_133983.2 CD276 antigen 
440799 2.7 0.0451 Slc2a1 NM_011400.1 solute carrier family 2 (facilitated glucose transporter), member 1 
760102 3.4 0.0295 Sdc1 NM_011519.1 syndecan 1 
779189 4.0 0.0169 Tmem104 NM_001033393.1 transmembrane protein 104 
97 genes that could be grouped by functional annotation using DAVID bioinformatics 
ressources; FC: fold change between WT and Oct-6-deficient FLMs after poly(I:C) 
treatment; within groups sorted by FC; GO-BP: GO biological process; GO-MF: GO 
molecular function; GO-CC: GO cellular compartment. 
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Validation of microarray data 
Out of the differentially expressed genes, 7 candidate genes (Dapp1, Dyrk1b, E4f1, Lsm10, Map3k12, 
Stk40, and Zdhhc3) were selected for validation by RT-qPCR. The selection was based on the 
significance of the fold-difference between the 2 genotypes after poly(I:C) treatment, on the amplitude 
of the difference, on the amplitude of the induction/reduction of gene expression in the WT and, 
finally, on the biological function of the respective gene product (table App. 5).  
The gene expression differences between WT and Oct-6-deficient FLMs could be verified for 2 genes, 
namely U7 snRNP-specific Sm-like protein LSM10 (Lsm10) and serine/threonine kinase 40 (Stk40). 
The expression level of Lsm10 in WT cells was not significantly changed in response to poly(I:C) 
treatment, whereas in the absence of Oct-6 the expression was reduced by approximately 2-fold 
(Figure 33A). Stk40 was induced about 7-fold upon poly(I:C) treatment in WT cells, whereas the 
induction in the absence of Oct-6 was only 3-fold (Figure 33B). For Lsm10 as well as for Stk40 the 
qPCR data showed high correlation with the microarray data (Figure 33C).  
 
 
  
 
Figure 33: Stk40 and Lsm10 are differentially expressed between WT and Oct-6-deficient 
FLMs after poly(I:C) treatment. WT and Oct-6-deficient FLMs were treated with poly(I:C)  
(50 µg/ml) for 8 hours, or were left untreated (0h). N-fold expression levels of (A) Lsm10 and (B) 
Stk40 relative to untreated WT cells (WT_0h = 1) were determined by RT-qPCR, applying the 
standard curve method and normalising to Ube2d2 (mean values ± SE of 6 independent 
experiments are shown; ***, p<0.001). (C) Microarray data for Lsm10 and Stk40.  
 
 
 
(A) (B) 
(C) 
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For the 5 additional genes tested, the differential expression patterns seen in the microarray could not 
be reproduced by RT-qPCR (Figures App. 19). A possible reason is that the qPCR assays were not 
positioned in the same region like the microarray probes. The microarray probes were mostly 
positioned in the 3’ region of the mRNA, for Dyrk1b 2 isoforms differing in the 3’ region are known 
(NCBI, GenBank), for Map3k12 alternative splice variants are described, differing in the 5’ part of the 
mRNA. No differential isoforms are known for Dapp1, E4f1 and Zdhhc3. Differential expression seen 
in the microarray might still be true for alternative splice forms of the respective gene (Morey et al., 
2006).  
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DISCUSS I ON 
 
Oct-6 is a transcription factor, which is mainly involved in Schwann cell development (Jaegle et al., 
1996; Bermingham et al., 1996), but which has not been related to immunity yet. We found that IFNβ, 
and to a lesser extent IFNγ, induce expression of Oct-6 in fibroblasts and macrophages, with the 
expression/DNA-binding activity of Oct-6 being generally stronger in macrophages. Oct-6 expression 
was not only induced by exogenous IFN, but also in response to poly(I:C) treatment and viral 
infections. Since this induction of Oct-6 is abolished in the absence of Ifnar1, we conclude that it is 
dependent on auto-/paracrine type I IFN signalling. Oct-6 expression in response to poly(I:C) 
treatment or MCMV infection was strongly reduced in IFNβ-deficient macrophages indicating that it 
is mainly IFNβ that mediates the auto-/paracrine effects. Since Oct-6 expression is completely 
abolished in Ifnar1-deficient cells, but residual Oct-6 expression is still observed in the absence of 
IFNβ, we conclude that also IFNαs can contribute to the induction of Oct-6.  
With respect to the mechanism of induction, we could show that it is the canonical Jak/Stat signalling 
pathway which is mediating Oct-6 expression in response to type I IFN, as Oct-6 induction is largely 
dependent on Stat1, and partially dependent on Tyk2. Irf1, induced by Stat1 after IFN treatment, is 
known to be required for the expression of a subset of IFN-responsive genes (Honda and Taniguchi, 
2006). Involvement of Irf1 in Oct-6 regulation was excluded, as absence of Irf1 had no impact on  
Oct-6 expression. Therefore we assumed direct involvement of Stat1 in Oct-6 regulation. Notably, 
strongly delayed and weak Oct-6 expression was observed in the absence of Stat1, arguing for 
additional IFN activated pathways that also induce low levels of Oct-6. Using ChIP technology, we 
identified a Stat1-binding region approximately 500 bp upstream of the Oct-6 transcription start site. 
Two almost perfect GAS and one imperfect ISRE site were predicted within this region. However, at 
present we cannot tell which Stat1-containing complex binds to which of the predicted elements, i.e. a 
Stat1/Stat2/Irf9 complex (ISGF3) to the imperfect ISRE site, Stat1/Stat1 homodimers and/or 
Stat1/Stat3 heterodimers to one or both GAS motifs. Experiments using Stat2- (Park et al., 2000) 
and/or Irf9-deficient (Kimura et al., 1996) cells would answer the question whether ISGF3 binding to 
the ISRE is required for regulating Oct-6 expression. Deletion/mutation analyses in reporter gene 
construct-based systems would be necessary to characterise the exact binding sites. So far, we cannot 
exclude that other Stat1 binding sites (ISRE and/or GAS motifs) further up- or downstream are also 
involved in regulation of Oct-6 expression. The question to which extent Stat3 contributes to the 
regulation of Oct-6 could be addressed by studying Stat3-deficient cells (Alonzi et al., 2001). Oct-6 
induction in response to IFNs, via the Jak/Stat signalling pathway is a completely novel mechanism 
for regulating expression of Oct-6. Oct-6 regulation has been characterised best in Schwann cells, 
where a Schwann cell specific enhancer element located about 12 kb downstream of the Oct-6 
transcription start site is solely responsible for correctly timed expression of Oct-6 (Mandemakers et 
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al., 2000). The signals and transcription factors that input on this enhancer element are less well 
defined. Axonal contact is the major prerequisite, cAMP signalling and activation of NFκB are also 
involved (Svaren and Meijer, 2008; Birchmeier and Nave, 2008). Only recently, a G-protein coupled 
receptor family member, Gpr126, was found to be involved in the induction of Oct-6 via elevating 
cAMP levels in zebrafish (Monk et al., 2009). However, ligands, additional receptors and signalling 
molecules remain to be elucidated. Thus, cytokine- (i.e. IFN-) induced Oct-6 expression in fibroblasts 
and macrophages is a novel finding and is clearly different from the mechanism responsible for the 
differentiation-triggered induction of Oct-6 during Schwann cell development.  
 
We could further show that Oct-6 protein induced in response to IFNβ or poly(I:C) treatment localises 
to the nucleus. Oct-6 contains both, a nuclear localisation and a nuclear export signal, which are 
located in the POU homeodomain (Baranek et al., 2005). So far, no post-translational modifications 
have been observed that would impact on Oct-6 localisation and/or transcriptional activity, but it has 
been hypothesised that regulating the subcellular localisation of Oct-6 can control its transcriptional 
activity (Baranek et al., 2005). The finding that Oct-6 protein localises to the nucleus of macrophages 
after IFNβ and poly(I:C) treatment, prompted us to search for target genes, and therefore for the role 
of Oct-6 in the context of innate immune responses.  
Some other POU-transcription factor family members, i.e. Oct-1, Oct-2 or Brn-3a/b, are known to be 
involved in the regulation of immunity-related genes, such as IFNαs (Mesplède et al., 2005), IFNβ 
(Haggarty et al., 1991; Du and Maniatis, 1992) and iNOS (Kleinert et al., 2004). Based on the fact that 
all POU-proteins show similar binding characteristics (Herr and Cleary, 1995), we asked whether 
these genes are also targets of Oct-6. We further tested whether Egr2 and Pmp22, two genes known to 
be regulated by Oct-6 during Schwann cell development (Ghazvini et al., 2002; Ryu et al., 2007), are 
also Oct-6-responsive in fibroblasts and macrophages. Expression of these five candidate target genes 
was analysed under conditions when Oct-6 was either overexpressed or deleted, i.e. in gain- and loss-
of-function studies, respectively. In addition to this candidate target gene approach, a whole genome 
microarray experiment comparing WT and Oct-6-deficient cells in response to poly(I:C) treatment was 
performed to more globally search for Oct-6 target genes in the setting of an innate immune response.  
When overexpressing Oct-6 and also Oct-1, we found prolonged high-level expression of IFNβ and 
IFNαs (all subtypes) in contrast to a transient induction of type I IFNs after transfection of control 
plasmids. This might be due to a direct effect of Oct-6/Oct-1 by their binding to octamer motifs within 
the regulatory elements of murine IFNα/β genes (Mesplède et al., 2005; Haggarty et al., 1991; Du and 
Maniatis, 1992). In line with this, we could show weak binding of Oct-6, Oct-1 and Oct-2 to an 
oligonucleotide probe covering the region -110 to -139 upstream of the IFNβ transcription start site – a 
preliminary result which needs confirmation. Alternatively, Oct-6/Oct-1 might exert an indirect effect 
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by either enhancing expression of genes inducing IFNα/β expression, or by repressing genes involved 
in the shut-off of IFNα/β expression. Our data showing that also Oct-1 had an enhancing effect on 
type I IFN expression are in contrast to a previous report (Mesplède et al., 2005), where a repressing 
effect of Oct-1 on basal and virus-induced IFNα expression was observed. These contrasting results 
might be explained by the different experimental approaches that were followed. Oct-1 was transiently 
overexpressed in both studies. We analysed endogenous IFNα (all subtypes) expression, whereas 
Mesplède et al. (2005) measured luciferase activity from a co-transfected IFNα-11-specific reporter 
construct. With a reporter construct the genomic region tested is limited and some cis-regulatory 
elements also impacting on gene regulation might be missing. Mesplède et al. (2005) additionally 
report that in Oct-1-deficient fibroblasts IFNα (all subtypes) expression was enhanced.  
In contrast to the striking results of the Oct-6 overexpression experiments, neither IFNα nor IFNβ 
expression patterns were altered in the absence of Oct-6 in response to DNA transfection in 
fibroblasts, or after poly(I:C) treatment in macrophages. The reasons for this discrepancy between 
overexpression and loss-of-function experiments are multiple. Expression of endogenous Oct-6 might 
be too low to mediate a detectable effect on IFNα/β mRNA expression. Other POU-proteins, i.e.  
Oct-1 in fibroblasts and Oct-1 and Oct-2 in macrophages, could interfere with or compensate potential 
effects of Oct-6. In order to follow that question Oct-1/Oct-2 expression could be knocked-down in 
fibroblasts or macrophages and then the impact of Oct-6 on IFNα/β expression could be analysed. 
Moreover, it has to be considered that the Oct-6 knockout is generated by the targeted disruption of the 
DNA-binding domain by insertion of a β-galactosidase/neomycin cassette (Jaegle et al., 1996). No 
full-length Oct-6 protein can be produced from this mutated allele, but the presence of a truncated  
Oct-6 protein with residual activity cannot be formally excluded.  
Overexpression of Oct-6 in fibroblasts did not have an impact on iNOS expression. Actually, iNOS 
mRNA could not be detected in fibroblasts in any condition tested. In  macrophages, iNOS was 
strongly induced in response to poly(I:C), but its expression was independent of the presence of Oct-6. 
A conserved octamer motif is located about 50 bp upstream of the iNOS transcription start site and 
Oct-1, Oct-2 and Brn3a/b have activating effects on iNOS expression (Kleinert et al., 2004 and 
references therein). It might well be that either Oct-6 is not able to bind to the iNOS promoter or that a 
potential effect of the absence of Oct-6 is masked by the presence of other POU-proteins.  
The expression of Egr2 and Pmp22, known target genes of Oct-6 in Schwann cells, were not 
influenced either by overexpression or absence of Oct-6 in fibroblasts and macrophages. Additional 
factors cooperating with Oct-6 might be necessary to regulate expression of Schwann cell-specific 
genes. For example, Egr2 is known to be regulated synergistically by Oct-6 and Sox10 in Schwann 
cells (Svaren and Meijer, 2008) and Sox10 expression has so far not been reported in fibroblasts or 
Discussion  70 
macrophages according to the publicly available gene expression profiles database BioGPS 
(http://biogps.gnf.org/#goto=genereport&id=6663, December, 2009; Wu et al., 2009). 
 
In order to more globally analyse the role of Oct-6 in the context of an innate immune response, a 
whole genome microarray experiment was performed comparing the transcriptomes of WT and Oct-6-
deficient macrophages treated with poly(I:C). A subset of genes (n=200) was found to be differentially 
expressed after poly(I:C) treatment in the absence of Oct-6 (minimum fold change = 2; p<0.05). 
Expression levels of about two thirds of those genes were reduced, the rest showed enhanced 
expression in the absence of Oct-6. This is in accordance with reports in Schwann cells, where Oct-6 
can also exert activating (Egr2; Ghazvini et al., 2002) as well as repressing (Pmp22, Mbp, Mpz; Ryu 
et al., 2007) functions. Functional analysis of the differentially regulated genes revealed that the genes 
do not belong to one specific pathway, but to a number different ones, e.g. “regulation of 
transcription”, “mRNA splicing” or “ubiquitin cycle”. In line with our RT-qPCR data showing no 
impact of Oct-6 on IFNα/β expression, microarray data did not reveal any differences in IFN and/or 
ISG expression between WT and Oct-6-deficient cells after poly(I:C) treatment.  
Microarray data were validated for two genes, namely Stk40 and Lsm10. Poly(I:C) treatment resulted 
in an induction of Stk40 expression, which was less pronounced in the absence of Oct-6 indicating that 
Oct-6 is necessary to amplify the induction of Stk40 mRNA levels. To our knowledge, there are only 
two reports on Stk40, also known as SINK homologous serine/threonine kinase (SHIK), the first 
showing that overexpressed Stk40/SHIK inhibits NFκB and p53 mediated transcription (Huang et al., 
2003). The second, very recent report, shows that Stk40 is suppressed by another octamer-binding 
factor, i.e. Oct-4 (Pou5f1), in embryonic stem cells (Li et al., 2010). Stk40 induces differentiation of 
extraembryonic endoderm via activation of the Erk/MAPK pathway. The impact of reduced Stk40 
expression on the NFκB, p53 and Erk/MAPK pathway and consequently on the processes of innate 
immune responses might be an interesting topic for future studies. Lsm10 is not influenced by the 
treatment in WT cells, but absence of Oct-6 leads to a reduction of Lsm10 levels after poly(I:C) 
treatment. Thus, Oct-6 is necessary to sustain Lsm10 levels in macrophages after poly(I:C) treatment. 
Lsm10 encodes a protein of the U7 small nuclear ribonucleoprotein (snRNP) complex, which is 
involved in formation of the 3’end of canonical histone mRNAs (Schümperli and Pillai, 2004). 
Canonical histones are expressed in a strictly replication dependent manner and absence of 
components of the U7 snRNP complex leads to an arrest in G1 phase (Marzluff et al., 2008). As Oct-6 
regulates Lsm10 expression, it may consequently be involved in regulating cell cycle progression. 
Further effort is needed to validate other Oct-6 target genes and address their role in innate immunity.  
Cellular POU-proteins are able to regulate transcription of a number of DNA viruses (Latchman, 
1999). Oct-6, in particular, is involved in regulating expression of early and late viral gene expression 
of JC polyomavirus, which is assumed to be responsible for its glial-cell tropism. Oct-6 was strongly 
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induced in response to MCMV infection in macrophages as well as in fibroblasts (data not shown). 
We therefore analysed  MCMV replication rates in macrophages, but no differences were observed 
between WT and Oct-6-deficient cells. Thus, we conclude that Oct-6 has no direct effect on MCMV 
replication in macrophages.  
 
Experiments with the murine Schwann cell line SW10 demonstrated that also in Schwann cells Oct-6 
expression is induced in response to IFNβ treatment. However, Oct-6 expression levels/DNA-binding 
activity in response to IFNβ treatment were rather low, which is probably due to the immature 
phenotype of this cell line (Hai et al., 2002). It would be worthwhile to study the effect of IFNβ 
treatment on Oct-6 expression in primary Schwann cells in vitro and in vivo. In vivo experiments 
would be interesting with respect to cooperative effects of IFNβ treatment and axon-derived signals, 
e.g. cAMP signalling and NFκB activation (Svaren and Meijer, 2008), known to regulate Oct-6 
expression. Oct-6 is also expressed in the myelinating cells of the central nervous system (CNS), the 
oligodendrocytes, but no effect of the absence of Oct-6 on CNS myelination was reported (Schreiber 
et al., 1997). It is assumed that other POU-family members expressed in oligodendrocytes, i.e. Brn-1 
and Brn-2, can compensate for the loss of Oct-6. However, overexpression of Oct-6 in 
oligodendrocytes results in a myelination defect in the CNS, indicating that missexpression or altered 
relative abundances of POU-family members is detrimental for correct CNS development (Jensen et 
al., 1998). It would be interesting to analyse whether type I IFNs are able to induce expression of  
Oct-6 also in oligodendrocytes and what the impact on CNS myelination would be. A number of 
viruses are able to infect the CNS and induce demyelination in humans (e.g. JC polyomavirus, human 
immunodeficiency virus and measles virus) and in mice (e.g. Theiler’s virus, mouse hepatits virus and 
Semliki forest virus) (Stohlman and Hinton, 2001). Interestingly, neurons have been shown to induce 
type I IFN expression in response to virus infection in the CNS (Delhaye et al., 2006). In Schwann 
cells, Oct-6 is also strongly induced during regeneration processes resulting in remyelination after 
injury. Interestingly, Schwann cells are not only involved in remyelination in the PNS but also in the 
CNS. Schwann cells invading the CNS after demyelination (Jasmin and Ohara, 2002) or derived from 
progenitor cells within the CNS (Blakemore, 2005) are able to remyelinate demyelinated axons, 
thereby sustaining nerve integrity until they are removed by astrocytes and oligodendrocytes can take 
over to restore a long-lasting myelin sheath (Jasmin and Ohara, 2002). Further studies could address 
the role of type I IFN production and Oct-6 induction on nerve regeneration, especially in the context 
of virus induced neuropathologies, but also in the conext of other demyelinating diseases, the most 
prominent being multiple sclerosis.  
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S U M M A R Y  
In summary, we have shown for the first time that (i) the POU-family transcription factor Oct-6 is 
induced in response to type I and type II IFNs – as opposed to the exclusively developmental context 
which Oct-6 has so far been related to, that (ii) this induction is dependent on canonical Jak/Stat 
signalling, which adds a novel facet to the regulatory elements involved in Oct-6 gene regulation, that 
(iii) Oct-6 is induced in fibroblasts and macrophages, cell types that have not been described before to 
express Oct-6, and that (iv) Oct-6 is able to modulate the transcriptional responses to poly(I:C) in 
macrophages. Collectively, these results reveal a novel role for Oct-6 as (co-) activator/repressor of 
transcription in the context of innate immunity.  
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APPENDIX 
 
Preliminary Results 
Various additional experiments were performed in order to either check for Oct-6 expression or to 
investigate a role of Oct-6 in innate immunity. No independent repeats were performed for these 
experiments.  
 
Screening of various murine cell types for expression of Oct-6 
In order to test, whether Oct-6 is also expressed in other cell types, B-cells, T-cells, NK-cells, BMMs 
and FLMs were treated with IFNβ and the composition of the octamer-binding factors was analysed 
by a bandshift assay. The preliminary results showed, that as expected, Oct-1 was present in all cell 
types and major expression of Oct-2 was found in B-cells and macrophages (Figure App. 1). Under 
basal conditions Oct-6 was not detected in any cell type. In contrast to fibroblasts and macrophages 
Oct-6 DNA-binding activity was not induced in B-cells, T-cells or NK-cells.  
 
 
 
Figure App. 1: Oct-6 is induced in pMEFs and macrophages, but not in the other cell types 
tested. B-cells (α-CD19 MACSed from splenocytes), T-cells (splenocytes activated with ConA or 
α-CD3ε), NK-cells (α-Dx5 MACSed from splenocytes), BMMs, FLMs and pMEFs were treated 
with IFNβ (1000 U/ml) for the indicated times. Whole cell extracts were analysed by a bandshift 
assay with an octamer motif-containing oligonucleotide (SS: supershift with an α-Oct-6 antibody 
from BMMs_IFNβ_8h; OX: overexpression of Oct-6 in a MEF line). 
 
 
Comparison of the induction of Oct-6 in BMMs and FLMs 
Due to the perinatal lethal phenotype of Oct-6-deficient mice, we had to establish fetal liver-derived 
macrophage (FLM) cultures as an alternative macrophage population instead of BMMs which we 
routinely use. In a preliminary experiment we prooved, that IFNβ and poly(I:C) also induced Oct-6 
DNA-binding activity in FLMs (Figure App. 2).  
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Figure App. 2: Oct-6 DNA-binding activity in response to IFNβ or poly(I:C) treatment is 
also induced in FLMs. FLMs and BMMs were treated with IFNβ (1000 U/ml), poly(I:C)  
(50 µg/ml) for the indicated times, or left untreated. Whole cell lysates were analysed by a 
bandshift assay using an oligonucleotide containing the octamer consensus motif (SS: supershift of 
the FLM_IFNβ_6h and FLM_poly(I:C)_6h lysate with an α-Oct-6 specific antibody).  
 
 
Candidate target gene expression in pMEFs: poly(I:C) transfection (with or without IFNβ 
pretreatment), MCMV infection 
In addition to the DNA transfection experiments described in the results section, preliminary 
experiments analysing the effect of Oct-6 deficiency in pMEFs on candidate target gene expression in 
response to poly(I:C) transfection with or without IFNβ pretreatment, and after MCMV infection were 
performed.  
As expected, transfection of pMEFs with poly(I:C) resulted in a strong increase of IFNβ and panIFNα 
expression (Figures App. 3A, B), whereas Egr2 expression seemed to be slightly reduced 24 hours 
after poly(I:C) transfection (Figure App. 3C) and Pmp22 expression levels were unchanged (Figure 
App. 3D). No effect of the absence of Oct-6 on target gene expression could be observed.  
 
Figure App. 3 – continued on the following page.  
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Figure App. 3: Absence of Oct-6 has no impact on candidate target gene expression in 
pMEFs after poly(I:C) treatment. WT (Oct6+/+) and Oct-6-deficient (Oct6-/-) pMEFs (from 
separate fetuses (“A”, “B”)) were transfected with poly(I:C) (200 ng/106 cells). After the indicated 
times total RNA was isolated. Changes in (A) IFNβ, (B) panIFNα, (C) Egr2 and (D) Pmp22 
mRNA compared to the untransfected (Ctrl) WT sample were determined by RT-qPCR, 
calculating n-fold expression levels by the ΔΔCt method normalising to Ube2d2 (only unicates 
were run for each sample). 
 
In order to increase Oct-6 levels, pMEFs were treated with IFNβ followed by poly(I:C) transfection, 
but again no difference in candidate target gene expression between the genotypes was observed 
(Figure App. 4A, B).   
 
 
Figure App. 4: Absence of Oct-6 has no impact on IFNα/β expression in pMEFs after 
poly(I:C) treatment with IFNβ pretreatment. WT (Oct6+/+) and Oct-6-deficient (Oct6-/-) 
pMEFs (from separate fetuses (“A”, “B”)) were treated with IFNβ (1000 U/ml for 14 hours) 
followed by transfection with poly(I:C) (200 ng/106 cells). After the indicated times total RNA 
was isolated. Changes in (A) IFNβ and (B) panIFNα mRNA compared to the untransfected (Ctrl) 
WT sample were determined by RT-qPCR, calculating n-fold expression levels by the ΔΔCt 
method normalising to Ube2d2 (only unicates were run for each sample). 
 
Furthermore WT and Oct-6-deficient pMEFs were infected with MCMV and candidate gene 
expression was analysed. As expected, IFNβ expression was highly increased in response to MCMV 
infection (Figure App. 5A), whereas expression of panIFNα was only slightly increased (Figure App. 
5B). Expression of Egr2 was not influenced by viral infection (Figure App. 5C), Pmp22 mRNA levels 
were slightly increased (about 2-fold) 12 hours after infection (Figure App. 5D). However, candidate 
target gene expression was independent of Oct-6.  
(C) (D) 
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Figure App. 5: Absence of Oct-6 has no impact on candidate target gene expression in 
pMEFs after MCMV infection. WT (Oct6+/+) and Oct-6-deficient (Oct6-/-) pMEFs (from 
separate fetuses (“A”, “B”)) were infected with MCMV at an MOI of 1. After the indicated times 
total RNA was isolated. Changes in (A) IFNβ, (B) panIFNα, (C) Egr2 and (D) Pmp22 mRNA 
compared to the uninfected (mock) WT sample were determined by RT-qPCR, calculating n-fold 
expression levels by the ΔΔCt method normalising to Ube2d2 (only unicates were run for each 
sample). 
 
 
Candidate target gene expression in FLMs: poly(I:C) kinetic and titration (with or without IFN 
pretreatment) 
In addition to the 8 hours poly(I:C) treatment described in the results section, preliminary experiments 
analysing the effect of Oct-6 deficiency in FLMs on candidate target gene expression were performed. 
These experiments included (a) a detailed kinetic of poly(I:C) treatment, (b) down-titration of 
poly(I:C), (c) IFNβ and IFNγ treatments prior to poly(I:C) stimulation.  
In order to test if Oct-6 is involved in gene regulation at another time than 8 hours after poly(I:C) 
treatment, a timecourse experiment was performed. As expected and already shown in the results 
(Figure 27A, B), expression of IFNα/β was highly induced in response to poly(I:C) treatment, with a 
1000-fold induction reached already after 3 hours, peaking 6 hours of treatment (Figures App. 6A, B). 
Similarly, expression levels of iNOS were strongly induced in response to poly(I:C) treatment (Figure 
App. 6C). Expression levels of Egr2 (Figure App. 6D) and Pmp22 (Figure App. 6E) varied 
considerably between the different FLM preparations. Expression of both genes was clearly reduced 
upon poly(I:C) treatment. However, all observed expression patterns were not influenced by the 
presence/absence of Oct-6 at any time point tested. 
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Figure App. 6: Absence of Oct-6 has no impact on candidate target gene expression in FLMs 
after poly(I:C) treatment (kinetic). WT (Oct6+/+) and Oct-6-deficient (Oct6-/-) FLMs (from 
separate fetuses (“A”, “B”)) were treated with poly(I:C) (50 µg/ml) for the indicated times. 
Changes in (A) IFNβ, (B) panIFNα, (C) iNOS, (D) Egr2 and (E) Pmp22 mRNA levels compared 
to an untreated (Ctrl) WT sample were determined by RT-qPCR, calculating n-fold expression 
levels by the ΔΔCt method normalising to Ube2d2 (only unicates were run for each sample).  
 
 
Considering that Oct-6 expression under the conditions tested so far might be too low to show an 
effect on target gene expression, FLMs were pretreated with IFNβ or IFNγ for different times prior to 
poly(I:C) treatment to increase Oct-6 expression. Treatment with IFNβ or IFNγ  alone does not induce 
IFNα/β expression (Figures App. 7-9A, B). After poly(I:C) treatment expression of IFNα/β mRNA is 
highly induced independent of the pretreatment. Expression of iNOS is induced one hour after 
poly(I:C) treatment with short (4 hours) IFNβ pretreatment (Figure App. 7C). With a long (12 gours) 
IFNβ pretreatment, iNOS induction in response to poly(I:C) is delayed (Figure App. 8C). In both cases 
IFNβ treatment alone did not induce iNOS expression. In contrast, IFNγ treatment alone induced high 
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amounts of iNOS (App. 9C), poly(I:C) treatment could further increase iNOS expression after IFNγ 
pretreatment. Expression patterns of IFNβ, IFNα and iNOS were independent of the presence/absence 
of Oct-6 upon any treatment tested.  
 
 
 
Figure App. 7: Absence of Oct-6 has no impact on candidate target gene expression in FLMs 
after short IFNβ pretreatment followed by poly(I:C) treatment. WT (Oct6+/+) and Oct-6-
deficient (Oct6-/-) FLMs (from separate fetuses (“A”, “B”)) were treated with IFNβ (1000 U/ml) 
for 4 hours, followed by poly(I:C) (50 µg/ml) treatment for the indicated times. Changes in (A) 
IFNβ, (B) panIFNα and (C) iNOS mRNA levels compared to an untreated (Ctrl) WT sample were 
calculated as decribed in Figure App. 6.  
 
 
Figure App. 8 – condtinued on the following page. 
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Figure App. 8: Absence of Oct-6 has no impact on candidate target gene expression in FLMs 
after long IFNβ pretreatment followed by poly(I:C) treatment. WT (Oct6+/+) and Oct-6-
deficient (Oct6-/-) FLMs (from separate fetuses (“A”, “B”)) were treated with IFNβ (1000 U/ml) 
for 12 hours, followed by poly(I:C) (50 µg/ml) treatment for the indicated times. Changes in (A) 
IFNβ, (B) panIFNα and (C) iNOS mRNA levels compared to an untreated (Ctrl) WT sample were 
calculated as decribed in Figure App. 6.  
 
 
 
 
 
Figure App. 9: Absence of Oct-6 has no impact on candidate target gene expression in FLMs 
after long IFNγ pretreatment followed by poly(I:C) treatment. WT (Oct6+/+) and Oct-6-
deficient (Oct6-/-) FLMs (from separate fetuses (“A”, “B”)) were treated with IFNγ (1000 U/ml) 
for 12 hours, followed by poly(I:C) (50 µg/ml) treatment for the indicated times. Changes in (A) 
IFNβ, (B) panIFNα and (C) iNOS mRNA levels compared to an untreated (Ctrl) WT sample were 
calculated as described in Figure App. 6.  
 
 
 
 
(C) 
(A) (B) 
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Based on the hypothesis that the standard poly(I:C) concentration of 50 µg/ml might be too high and 
thus leading to a saturation effect in IFNα/β expression, consequently masking a potential effect of the 
absence of Oct-6, the amount of poly(I:C) was gradually reduced to concentrations as low as 5 ng/ml. 
Similar high amounts of IFNβ mRNA were induced with 50 µg/ml (Figure App. 6A) poly(I:C) and 
with concentrations as low as 500 ng/ml (Figure App. 10A, B). An effect of poly(I:C) reduction on 
IFNβ mRNA induction was observed with 50 ng/ml (Figure App. 10C) and 5 ng/ml poly(I:C) (Figure 
App. 10D). Induction of IFNα was similarly high with 50 µg/ml (Figure App. 6B) and 5 µg/ml (Figure 
App. 11A) poly(I:C). With reduction of poly(I:C) to 50 ng/ml (Figure App. 11B, C), panIFNα 
induction was lower, with 5 ng/ml poly(I:C) panIFNα was not detectable (data not shown). However, 
no differences in IFNα/β expression between WT and Oct-6-deficient FLMs could be observed at any 
concentration or time point. 
 
 
 
Figure App. 10: Absence of Oct-6 has no impact on IFNβ expression in response to various 
concentrations of poly(I:C) in FLMs. WT (Oct6+/+) and Oct-6-deficient (Oct6-/-) FLMs (from 
separate fetuses (“A”, “B”)) were treated with (A) 5 µg/ml, (B) 500 ng/ml, (C) 50 ng/ml or (D) 5 
ng/ml poly(I:C) for the indicated times. Changes in IFNβ mRNA compared to an untreated WT 
sample were calculated as described in Figure App. 6.  
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(C) (D) 
Appendix  87 
 
  
Figure App. 11: Absence of Oct-6 has no impact on panIFNα expression in response to 
poly(I:C) treatment in FLMs. Experimental setup and calculation of n-fold expression levels as 
described in Figure App. 10 and 6, respectively.  
 
 
 
Expression of IFNα subtypes in Oct-6-deficient FLMs 
Based on a report claiming that Oct-1 represses distinct IFNα subtypes (Mesplede et al., 2005), 
expression levels of IFNα-1 and IFNα-2 in WT and Oct-6-deficient FLMs were determined by 
semiquantitative PCR. Preliminary results showed, that IFNα-subtypes were induced after treatment 
with poly(I:C) alone (Figure App. 12A) or with IFNβ pretreatment prior to poly(I:C) treatment (Figure 
App. 12B). No differences in IFNα subtype expression between the genotypes could be observed.  
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Figure App. 12: Absence of Oct-6 does not influence the expression of IFNα-1 and IFNα-2.  
WT (Oct-6+/+) and Oct-6-deficient (Oct-6-/-) FLMs (separate cell preparations “A”, “B”) were 
(A) treated with poly(I:C) (500 ng/ml), or (B) pretreated with IFNβ (1000 U/ml) followed by 
poly(I:C) treatment (50 µg/ml). Expression of IFNα-1 and IFNα-2 was determined by 
semiquantitative PCR: 5-fold dilution series of the respective cDNAs were amplified and the 
amplification products were separated on a 2% agarose gel stained with ethdium bromide (M: size 
marker). Similar expression of the endogenous control Ube2d2 has been checked by qPCR before 
(data not shown).   
 
 
 
Binding of POU-transcription factors to consensus motifs in the IFNβ promoter  
A number of potential octamer-binding sites are present in the murine IFNβ promoter (Haggarty et al., 
1991). In bandshift experiments, using two oligonucleotide probes covering the regions -110 to -139 
(IFNβ_1) and -78 to -113 (IFNβ_2) (Figure App. 13A), we tested wether Oct-6 is able to bind to the 
motifs within the murine IFNβ promoter. FLMs were treated with poly(I:C) and whole cell extracts 
were used to shift an oligonucleotide containing the standard octamer consensus motif (OCT), IFNβ_1 
or IFNβ_2. As expected and shown before, strong binding of Oct-6 was observed with the OCT-probe. 
Weak binding of Oct-6, but also of Oct-1 and Oct-2, to IFNβ_1 could be observed (Figure App. 13B). 
No binding pattern resembling the Oct-protein pattern was observed with the IFNβ_2 probe.  
 
 
(A) 
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Figure App. 13: POU-proteins are able to bind to consensus motifs of the murine IFNβ 
promoter. (A) Comparison between the human (Du and Maniatis, 1992) and the murine IFNβ 
promoter with the respective transcription factor binding sites (potential octamer motifs: italic and 
underlined). The two oligonucleotides (IFNβ_1 and IFNβ_2) used for the bandshift experiment are 
indicated. (B) WT and Tyk2-/- BMMs were treated with poly(I:C) (50 µg/ml) for the indicated 
times. Whole cell extracts were analysed by a bandshift assay with an octamer motif-containing 
probe (OCT) and two oligonucleotides covering potential octamer motifs in the murine IFNβ 
promoter (IFNβ_1 and IFNβ_2), (SS: Supershift of WT_8h lysates with an α-Oct-6 antibody).  
 
 
Activation of signalling pathways in Oct-6-deficient FLMs 
In order to test effects of the absence of Oct-6 on the activation of pathways involved in the response 
to poly(I:C) treatment, NFκB and p38 mitogen-associated protein kinas (MAPK) activation was 
analysed in WT and Oct-6-deficient macrophages. Preliminary results showed that NFκB was 
similarly activated (serine-536 phosphorylation of the p65 subunit; Figure App. 14A).  
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Also after pretreatment with IFNβ for 2 days followed by poly(I:C) treatment similar activation of 
NFκB (Figure App. 14B) was observed in WT and Oct-6-deficient macrophages. Also activation of 
p38 MAPK observed in response to poly(I:C) and combined IFNβ pre-/poly(I:C) treatment (Figures 
App 14C, D) was similar in WT and Oct-6-deficient cells.  
 
 
 
 
 
 
Figure App. 14: Activation of the NFκB- and the p38 MAPK-pathway are not influenced by 
the absence of Oct-6. WT and Oct-6-deficient FLMs were (A, C) treated with poly(I:C) (50 
µg/ml), or (B, D) pretreated with IFNβ (1000 U/ml for two days) followed by poly(I:C) treatment 
for the indicated times. Whole cell extracts were analysed by western blot with antibodies 
detecting (A) Serine-536-phosphorylated (Ser536-P) NFκB p65, (B) NFκB p65, (C) 
phosphorylated (P) p38 MAPK and (D) p38 MAPK. All blots were reprobed with an α-panERK 
specific antibody to control for equal loading.  
 
 
MCMV replication in Oct-6-deficient FLMs: lower MOI, standard MOI with or without IFN 
pretreatment  
In addition to the standard MOI of 1 for MCMV infections, lower virus dose (i.e. MOI of 0.1) and IFN 
treatment prior to infection was analysed in WT versus Oct-6-deficient FLMs. As expected, MCMV 
replicated to lower titres at a lower MOI (Figure App. 15A compare to Figure 28 in the results section) 
and IFNβ as well as IFNγ pretreatment reduced viral replication (Figure App. 15B-D, compare to 
Figure 28). Preliminary data showed no effect of Oct-6 on MCMV replication under any of those 
conditions.  
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Figure App. 15: The absence of Oct-6 does not influence MCMV replication in FLMs. WT 
and Oct-6-deficient FLMs (separate FLM preparations “A”, “B”) were (A) infected with MCMV 
(MOI=0.1), (B) pretreated with IFNβ for 4 hours, (C) for 12 hours or (D) pretreated with IFNγ for 
12 hours followed by infection with MCMV (MOI=1). Supernatants were taken one hour (d0), 1, 3 
and 6 days (d) after infection. Virus titres were determined in a plaque forming assays on Stat1-
deficient MEFs. Mean values ± SD of technical duplicates are shown.  
 
 
Details of microarray results 
Functional annotation of genes regulated in response to poly(I:C) 
Poly(I:C) treatment had a major impact on the macrophage transcriptome as about 1200 genes were 
up- and 2300 genes downregulated in WT FLMs. Functional annotation and statistical analysis 
(GeneSpring Expression Analysis 7.3.1 tool, Agilent Technologies) revealed that genes upregulated in 
response to poly(I:C) were significantly enriched in immunity-related GO-categories, such as “defense 
response”, “immune response” or “response to virus” (table App. 1). In contrast, genes downregulated 
after poly(I:C) treatment were enriched in metabolism-related GO-categories, e.g. “DNA metabolism”, 
“macromolecule metabolism” or “biopolymer metabolism” (table App. 2).  
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Genes involved in “apoptosis” and “cell death” were up-regulated, whereas genes necessary for “cell 
cycle” and “mitosis” were down-regulated in response to poly(I:C) underlining the proapoptotic nature 
of an antiviral response in this case provoked by poly(I:C) treatment.  
 
Table App. 1: GO “biological process” categories upregulated in WT upon poly(I:C) treatment 
(top 30 categories; sorted by significance of enrichment). 
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Table App. 2: GO “biological process” categories downregulated in WT upon poly(I:C) 
treatment (top 30 categories; sorted by significance of enrichment). 
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Detailed list of Oct-6 target genes in FLMs after poly(I:C) treatment 
A subset of 201 genes was found to be differentially regulated between WT and Oct-6-deficient FLMs 
after poly(I:C) treatment, 125 reduced (table App. 3), 86 induced (table App. 4). These results indicate 
that Oct-6 exerts positive and negative functions in regulating transcriptional responses to poly(I:C).  
 
Table App. 3: Genes significantly reduced in the absence of Oct-6 in FLMs after poly(I:C) 
treatment (at least 2-fold change (FC), p<0.05; genes sorted by FC). 
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Table App. 4: Genes significantly enhanced in the absence of Oct-6 in FLMs after poly(I:C) 
treatment (at least 2-fold change (FC), p<0.05; genes sorted by FC).  
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Validation of microarray data: supplemental data 
As shown in the results, 2 out of 7 genes were positively validated for differential expression between 
WT and Oct-6-deficient macrophages after poly(I:C) treatment (Figure 33). For the rest of the genes, 
namely Dapp1, Dyrk1b, E4f1, Map3k12 and Zdhhc3, microarray results (table App. 5) could not be 
reproduced by RT-qPCR (Figure App. 17A-E). According to the microarray data, expression levels of 
Dyrk1b and Zdhhc3 were not altered upon treatment in WT cells, but up- or downregulated in the 
absence of Oct-6, but RT-qPCR results showed similar regulation of mRNA levels in both genotypes. 
Microarray data showed a reduction of E4f1 and Map3k12 expression levels after treatment in WT 
cells, but constant or less reduced levels in the absence of Oct-6, respectively. RT-qPCR showed 
similar reduction of E4f1 and Map3k12 expression in both genotypes.  
According to the microarray data, Dapp1 was induced about 3-fold in WT FLMs. In the absence of 
Oct-6, expression levels of Dapp1 were about 2-fold lower after poly(I:C) treatment in comparison the 
WT situation. RT-qPCR analysis showed that Dapp1 is neither induced in the WT, nor is it reduced in 
the absence of Oct-6 (Figure App. 17A).  
A possible reason for the discrepancy between microarray and RT-qPCR results is that the qPCR 
assays were not positioned in the same region as the microarray probes. The microarray results might 
still be right for alternative splice forms (Morey et al., 2006). In order to test this possibility, it would 
be necessary to design qPCR assays located within the respective microarray probe sequence.  
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Table App. 5: Microarray data for the genes showing different expression patterns in 
microarray versus RT-qPCR analysis.   
gene symbol 
(gene name) 
probe_ID 
RefSeq 
WT inducibility 
(mean ± SD) 
Oct6-/- vs. WT  
after poly(I:C)  
(mean ± SD) 
P-value for  
Oct6-/- vs. WT 
after poly(I:C) 
Dapp1  
(dual adaptor for phospho-tyrosine and 3-
phospho-inositides 1) 
495637 
NM_011932.1 3.1 ± 1.6 0.49 ± 0.096 0.0062 
Dyrk1b 
(dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1b) 
464717 
NM_010092.1 1.1 ± 0.4 4.8 ± 2.45 0.0077 
E4f1 
(E4F transcription factor 1) 
906799 
NM_007893.1  0.3 ± 1.5 3.3 ± 0.38 0.0034 
Map3k12 
(mitogen-activated protein kinase kinase 
kinase 12) 
922907 
NM_009582.2 0.3 ± 0.1 0.39 ± 0.108 0.0156 
Zdhhc3 
(zinc finger, DHHC domain containing 3) 
617536 
NM_026917.4 1.0 ± 0.2 0.23 ± 0.131 0.0124 
 
 
Figure App. 17 – continued on the following page.  
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Figure App. 17: RT-qPCR data for the genes showing different expression patterns in 
microarray versus RT-qPCR analysis.  WT and Oct-6-deficient FLMs were treated with 
poly(I:C) (50 µg/ml) for 8 hours. For validation, cDNA of the same RNA samples that had been 
analysed on the microarray, was used. N-fold expression levels of (A) Dapp1, (B) Dyrk1b, (C) 
E4f1, (D) Map3k12 and (E) Zdhhc3 were determined by RT-qPCR, applying the ΔΔCt method, 
normalising to Ube2d2 (mean values of technical duplicates ± SD are shown).  
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